

# Scott Richard Evans

## Office 1:

The Biostatistics Center  
George Washington University  
6110 Executive Boulevard  
Suite 750  
Rockville, MD 20852-3943  
Tel: (301) 881-9260  
FAX: (301) 881-3742  
Email: [sevans@bsc.gwu.edu](mailto:sevans@bsc.gwu.edu)  
<http://biostatcenter.gwu.edu/people/admin-leadership/scott-evans>

## Office 2:

Department of Biostatistics and Bioinformatics  
800 22<sup>nd</sup> St, NW  
7th Floor - Office 7810  
Washington, DC 20052  
Tel: (202) 994-4821  
<https://publichealth.gwu.edu/departments/biostatistics-and-bioinformatics/scott-evans>

## **Education and Training**

Plymouth State College	B.S.	Mathematics	1988
University of New Hampshire	M.S.	Mathematics	1990
University of Massachusetts	Ph.D.	Biostatistics	1998

## **Professional Employment**

### ***Appointments***

Founding Chair	2019-present	Department of Biostatistics and Bioinformatics (DBB), George Washington University
Professor, Tenured	2019-present	DBB, George Washington University
Professor, Tenured	2018-2019	Department of Epidemiology and Biostatistics, George Washington University
Director	2018-present	Biostatistics Center (BSC), George Washington University
Adjunct Professor	2018	Department of Biostatistics Harvard University

### ***Prior Appointments***

Senior Research Scientist	2007-2018	Department of Biostatistics, Harvard University
Research Scientist	2002-2006	Department of Biostatistics, Harvard University
Research Associate	2000-2001	Department of Biostatistics, Harvard University

### ***Principal Responsibilities***

- Leading the scientific direction and operational administration for the BSC
- Hiring, mentoring, and evaluation of BSC faculty

- Leading the educational curriculum and operational administration for the DBB
- Hiring, mentoring, and evaluation of DBB faculty
- Principal Investigator for the Statistical and Data Management Centers (SDMC) for the Antibacterial Resistance Leadership Group (ARLG)
- Teaching related to clinical trials
- Mentoring of students

### ***Leadership Roles***

2019-present Chair, DBB  
 2019-present Executive Committee for the Milken Institute School of Public Health  
 2018-present Chair, Executive Committee of the BSC  
 2018-present Chair, Steering Committee of the BSC  
 2018-present Innovations in Design, Education, and Analysis (IDEA) Committee  
 2018-present Funding Opportunities and Faculty Issues Committee

### ***Prior Leadership Roles at Harvard University***

2014-2018 Center for Biostatistics in AIDS Research (CBAR) Steering Committee  
 2011-2015 Co-Chair, CBAR Design Review Committee  
 2010-2014 CBAR Training Committee

### ***Leadership Roles within the Clinical Research Networks***

#### *Antibacterial Resistance Leadership Group (ARLG)*

2020-present Innovations Working Group  
 2013-present Executive Committee  
 2013-present Vice-chair, Steering Committee  
 2013-present Director, SDMC  
 2013-2020 Mentoring Committee

#### *Exercise and Nutrition Interventions to Improve Cancer Treatment-Related Outcomes (ENICTO) in Cancer Survivors Consortium*

2022-present Principle Investigator, Coordinating Center  
 2022-present Steering Committee

#### *Neurologic AIDS Research Consortium (NARC)*

2002-2012 Executive Committee  
 2002-2012 Director, SDMC

#### *Oral HIV/AIDS Research Alliance (OHARA)*

2006-2013 Steering Committee

#### *AIDS Clinical Trials Group (ACTG)*

2012-2013 Neurology Steering Committee and SDMC Section Head  
 2011-2013 End Organ Disease / Inflammation Steering Committee and SDMC Section Head  
 2011-2013 Coinfections and Malignancies Steering Committee and SDMC Section Head  
 2006-2011 OpMAN Steering Committee and SDMC Section Head  
 2004-2007 Co-Chair, Data Management Committee

### **Honors and Awards**

2022 Distinguished Achievement Award, Teaching Statistics in the Health Sciences

Section, American Statistical Association (ASA)  
2021 Founders Award, ASA  
2019 Certificate of Appreciation, American Statistical Association (Retiring Editor)  
2018 Fellow, Society for Clinical Trials  
2018 Fellow, Infectious Disease Society of America  
2018 Elected Member, International Statistical Institute  
2018 Best Poster Award, ASA Biopharmaceutical Section Regulatory-Industry  
Statistics Workshop  
2016 Certificate of Achievement, International Chinese Statistical Association  
2016 Best Poster Award, ASA Biopharmaceutical Section Regulatory-Industry  
Statistics Workshop  
2015 Mosteller Award, Boston Chapter of the ASA  
2014 Best Contributed Paper, Joint Statistical Meetings (JSM), ASA  
2012 Fellow, ASA  
2011 Appreciation, Committee for Advanced Scientific Education, FDA  
2008 Harvard School of Public Health Recognition Award  
2008 Council of Chapters Distinguished Service Award, ASA  
2007 Meritorious Contributor Award, Biopharmaceutical Applied Statistics  
Symposium (BASS)  
2006 Robert Zackin Distinguished Collaborative Statistician Award, AIDS Clinical  
Trials Group (ACTG)  
2005 Mu Sigma Rho, the National Statistics Honorary Society, Faculty Inductee  
2004 Strategic Initiative Award: Outreach to Isolated Schools, ASA

### **Grants Awarded or Pending**

Antibacterial Resistance Leadership Group (ARLG)  
2 UM1AI104681-08 Fowler (PI) 12/01/19-11/30/2026  
NIH/NIAID (Subaward with Duke University)  
The ARLG is a national resource funded by NIAID to design, prioritize, conduct, and manage an integrated clinical research program to address antibacterial resistance scientific priorities.  
Role: Site PI; Director, Statistical and Data Management Center  
Percent Effort: 50% Yearly Direct Award: \$2,391,768

ENICTO Consortium Coordinating Center  
1 U24 CA271246-01 Evans (PI) 08/08/2022-06/30/2027  
NIH/NCI  
The goal of the Exercise and Nutrition Interventions to Improve Cancer Treatment-related Outcomes (ENICTO) Consortium is to support and enhance exercise and/or medical nutrition intervention research designed to evaluate interventions that may improve cancer treatment-related outcomes among patients being treated with curative or life-extending intent.  
Role: PI  
Percent Effort: 10% Total Award: \$4,930,468

Short Course versus Standard Course Antifungal Therapy for Pediatric Candidemia: A Multi-Center Randomized Controlled Trial (COUNT)  
NIH/NIAID (Subaward w/ Arkansas Children's Research Institute) 08/05/2022 – 07/31/2029  
The primary objective of the proposed randomized controlled trial is to determine whether 7 days of therapy is comparable to 14 days for the treatment for pediatric uncomplicated candidemia and if a molecular biomarker can add in safe cessation of therapy.



Development of ARV-1801 for Treatment of Post-Exposure Prophylaxis (PEP) of Melioidosis Arrebus date-date

Randomized, Double-Blind, Placebo-Controlled, Exploratory Study to Assess the Efficacy, Safety and Tolerability of Oral ARV-1801 Given in Combination with Intravenous Cefazidime or Meropenem for Intensive Phase Therapy of Melioidosis in Hospitalized Patients

Role: PI

Percent Effort: % Total Costs: \$

Development of ARV-1801 for Treatment of Pulmonary Exacerbations in Patients with Cystic Fibrosis

Aceragen date-date

A randomized, double-blind, placebo-controlled Phase 2 study is planned to evaluate the superiority of a 14-day oral loading dose regimen of ARV-1801 plus optimized background therapy (OBT) compared to placebo plus OBT in treatment of CF PEX.

Role: PI

Percent Effort: % Total Costs: \$

5 UM1 AI068634-10 Hughes (PI) 06/29/06 - 11/30/20  
NIH/NIAID

ACTG - Statistical and Data Management Center

Provides statistical and data management expertise and support to the AIDS Clinical Trials Group to conduct studies on the treatment of HIV-infected adults.

Role: Senior Statistician

Multidisciplinary NeuroAIDS Research Training to Improve HIV Outcomes in Nigeria

5 D43 TW009608-04 Taiwo (PI) 08/05/14-01/31/18

NIH/FIC (Subcontract of Northwestern, Evans (PI))

The program develops scientists who lead discovery of sustainable solutions for NeuroAIDS in Nigeria and amplify the benefits of HIV treatment for HIV infected individuals and society.

Role: Statistical Mentor

Percent Effort: 3% Yearly Direct Costs: \$7,319

RC4 CA155940-01 Wei (PI) 09/30/10 - 09/29/13  
NIH/NCI

Personalized Medicine in Comparative Effectiveness

This project developed novel statistical methods for personalized medicine in comparative effectiveness. These methods will allow more robust evidence-based decisions in clinical practice that are tailored to individual patients based on their personal characteristics, so that the best clinical decisions are made for individual patients and the efficiency in public health practice is optimized.

Role: Investigator

R01 AI052817 Wei (PI) 09/30/02 – 08/31/10  
NIH/NIAID

Statistical Methods for HIV/AIDS Studies

The focus of this project is to research censored regression problems that are encountered frequently in HIV/AIDS research.

Role: Investigator

U01 NS0322228 Clifford (PI) 08/01/2003 – 11/30/2011  
(Subcontract from Washington University, Evans (PI))  
NIH/NINDS

Neurologic AIDS Research Consortium (NARC)  
The NARC conducts studies of neurological complications of HIV.  
Role: Director, Statistical and Data Management Center, NARC

U01 AI068636-01                      Robertson (PI)                      06/01/2007 – 05/31/2013  
(Subcontract from Social and Scientific Systems, Evans (PI))  
NIH/NIMH  
International Neurological Study  
Multinational neurological and neuropsychological study in HIV.  
Role: Investigator and Senior Statistician

U01 AI068636-01                      Shiboski (PI)                      06/01/2007 – 05/31/2013  
(Subcontract from Social and Scientific Systems, Evans (PI))  
NIDCR/NIH  
Oral HIV/AIDS Research Alliance (OHARA)  
OHARA conducts studies of oral-health complications of HIV.  
Role: Investigator and Director of the Statistical and Data Analysis Center, OHARA

## Publications

### Articles in Refereed Journals

1. **Evans SR.** Independent Oversight of Clinical Trials through Data and Safety Monitoring Boards. *NEJM Evid* 2022; 1 (1). DOI: 10.1056/EVIDctw2100005
2. **Evans SR.** Zeng L, Dai W. The DSMB: The Toughest Job in Clinical Trials. Published January 24, 2023. *NEJM Evid* 2023; 2 (2). DOI: <https://doi.org/10.1056/EVIDctw2200220>.
3. **Evans SR.** Radical Thinking: Scientific Rigor and Pragmatism. *Statistics in Biopharmaceutical Research*, 14:2, 140-152, 2022. <https://doi.org/10.1080/19466315.2022.2026460>.
4. **Evans SR.** Our Most Important Discovery: The Question. *Statistics in Biopharmaceutical Research*, 14:4, 398-407, 2022. <https://doi.org/10.1080/19466315.2021.1972833>.
5. **Evans SR,** Hamasaki T. Weighing Evidence: Robustness vs. Quantity. *JNCI: Journal of the National Cancer Institute*, djac186, <https://doi.org/10.1093/jnci/djac186>. 2022.
6. Patel, R, Tsalik E, **Evans S,** Fowler jr VG, Doernberg S. Clinically Adjudicated Reference Standards for Evaluation of Infectious Diseases Diagnostics, *CID*, accepted 2022.
7. Howard-Anderson J, Hamasaki T, Dai W, Collyar D, Rubin D, Nambiar S, Kinamon T, Hill C, Gelone SP, Mariano D, Baba T, Holland TL, Doernberg SB, Chambers HF, Fowler VG, **Evans SR,** Boucher HW. Improving Traditional Registrational Trial Endpoints: Development and Application of a Desirability of Outcome Ranking (DOOR) Endpoint for Complicated Urinary Tract Infection Clinical Trials. *Clin Infect Dis*. 2022 Aug 29:ciac692. doi: 10.1093/cid/ciac692. Epub ahead of print. PMID: 36031403.
8. Kinamon T, Gopinath R, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, Evans SR, Hamasaki T, Holland TL, Howard-Anderson J, Chambers H, Fowler Jr VG, Nambiar S, Kim P, Boucher HW. Exploration of a Potential DOOR Endpoint for Complicated Intra-Abdominal Infections Using Nine Registrational Trials for Antibacterial Drugs, accepted, *CID*, 2023.
9. Turner NA, Zaharoff S, King H, **Evans SR,** Hamasaki T, Lodise T, Ghazaryan V, Beresnev T, Riccobene T, Patel R, Doernberg SB, Rappo U, Fowler VG Jr, Holland TL; Antibacterial Resistance Leadership Group (ARLG). Dalbavancin as an option for treatment of *S. aureus* bacteremia (DOTS): study protocol for a phase 2b, multicenter, randomized, open-label clinical trial. *Trials*. 2022 May 16;23(1):407. doi: 10.1186/s13063-022-06370-1. PMID: 35578360; PMCID: PMC9109297.
10. Howard-Anderson J, Dai W, Yahav D, Hamasaki T, Turjeman A, Koppel F, Franceschini E, Hill C, Sund Z, Chambers HF, Fowler, Jr. VG, Boucher HW, **Evans SR,** Paul M, Holland TL, Doernberg SB, A Desirability of Outcome Ranking Analysis of a Randomized Clinical Trial Comparing Seven Versus Fourteen Days of Antibiotics for Uncomplicated Gram-Negative Bloodstream Infection, *Open Forum Infectious Diseases*, Volume 9, Issue 6, June 2022, ofac140, <https://doi.org/10.1093/ofid/ofac140>.
11. Tamma PD, Souli M, Billard M Campbell J, Conrad D, Ellison DW, Evans B, **Evans SR** Greenwood-Quaintance KE Filippov AA, Geres HS, Hamasaki T, Komarow L, Nikolich MP, Lodise TP, Nayak SU, Norice-Tra C, Patel R, Pride D, Russell J, Van Tyne D, Chambers, HF, Fowler, VG, Schooley RT. Safety and Microbiological Activity of Phage Therapy in Persons with Cystic Fibrosis Colonized with *Pseudomonas aeruginosa*: Study Protocol for a Phase 1b/2, Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial. *Trials*, accepted, (2022) 23:1057 <https://doi.org/10.1186/s13063-022-07047-5>.
12. Tsalik EL, Roupheal NG, Sadikot RT, Rodriguez-Barradas MC, McClain MT, Wilkins DM, Woods CW, Swamy GK, Emmanuel D, Walter B, El Sahly HM Keitel WA, Mulligan MJ, Tuyishimire B, Serti E, Hamasaki T, **Evans SR,** Ghazaryan V, Lee MS, Lautenbach E. Randomised Clinical Trial of Azithromycin versus Placebo to Treat Lower Respiratory

- Tract Infections Associated with Low Procalcitonin. DOI:[https://doi.org/10.1016/S1473-3099\(22\)00735-6](https://doi.org/10.1016/S1473-3099(22)00735-6). *Lancet ID*, 2022.
13. Reyes J, Komarow L, Chen L, Ge L, Hanson BM, Cober E, Herc E, Alenazi T, Kaye KS, Garcia-Diaz J, Li L, Kanj SS, Liu Z, Oñate JM, Salata RA, Marimuthu K, Gao H, Zong Z, Valderrama-Beltrán SL, Yu Y, Tambyah P, Weston G, Salcedo S, Abbo LM, Xie Q, Ordoñez K, Wang M, Stryjewski ME, Munita JM, Paterson DL, **Evans S**, Hill C, Baum K, Bonomo RA, Kreiswirth BN, Villegas MV, Patel R, Arias CA, Chambers HF, Fowler, Jr. VG, Doi Y, van Duin D, Satlin MJ. Global Epidemiology and Clinical Outcomes of Carbapenem-resistant *Pseudomonas aeruginosa* and Associated Carbapenemases (POP): a Prospective Cohort Study. Accepted, *Lancet Microbe*, 2022. [https://doi.org/10.1016/S2666-5247\(22\)00329-9](https://doi.org/10.1016/S2666-5247(22)00329-9).
  14. Tamma P, Komarow L, Ge L, Garcia-Diaz J, Herc ES, Doi Y, Arias CA, Albin O, Saade E, Miller LG, Jacob JT, Satlin MJ, Krsak M, Huskins WC, Dhar S, Hill C, Baum KR, Bhojani M, Greenwood-Quaintance KE, Schmidt-Malan SM, Patel R, **Evans S**, Chambers HF, Fowler Jr. VG, van Duin D. Clinical Impact of Ceftriaxone Resistance in *Escherichia Coli* Bloodstream Infections: A Multicenter Prospective Cohort Study. Accepted, *OFID*, 2022.
  15. Kinamon T, Gopinath R, Waack U, Needles M, Rubin D, Collyar D, Doernberg SB, **Evans SR**, Hamasaki T, Holland TL, Howard-Anderson J, Chambers H, Fowler Jr VG, Nambiar S, Kim P, Boucher HW. Development and Analysis of a Novel DOOR Endpoint for Complicated Intra-abdominal Infections (cIAI) Using 10 Registrational Trials for Antibacterial Drugs, *Open Forum Infectious Diseases*, 9, Suppl2, ofac492.301, <https://doi.org/10.1093/ofid/ofac492.301>
  16. Wang Y, Pan Y, Li H, Amarenco P, Denison H, **Evans SR**, Himmelmann A, James S, Knutsson M, Ladvall P, Molina CA, Johnston SC. Time Course for Benefit and Risk of Ticagrelor and Aspirin in Acute Ischemic Stroke or Transient Ischemic Attack. *Neurology* Jul 2022, 99 (1) e46-e54; DOI: 10.1212/WNL.0000000000200355.
  17. Pettigrew MM, Kwon J, Gent JF, Kong Y, Wade M, Williams DJ, Creech CB, **Evans S**, Pan Q, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Fowler VG, Chambers HF, Huskins WC; Antibacterial Resistance Leadership Group. Comparison of the Respiratory Resistomes and Microbiota in Children Receiving Short versus Standard Course Treatment for Community-Acquired Pneumonia. *mBio*. 2022 Apr 26;13(2):e0019522. doi: 10.1128/mbio.00195-22. Epub 2022 Mar 24. PMID: 35323040; PMCID: PMC9040816.
  18. Kwon J, Kong Y, Wade M, Williams DJ, Creech CB, **Evans S**, Walter EB, Martin JM, Gerber JS, Newland JG, Hofto ME, Staat MA, Chambers HF, Fowler VG, Huskins WC, Pettigrew MM. Gastrointestinal Microbiome Disruption and Antibiotic-Associated Diarrhea in Children Receiving Antibiotic Therapy for Community-Acquired Pneumonia. *J Infect Dis*. 2022 Sep 21;226(6):1109-1119. doi: 10.1093/infdis/jiac082. PMID: 35249113; PMCID: PMC9492313.
  19. Hohenschurz-Schmidt D, Kleykamp BA, Draper-Rodi J, Vollert J, Chand J, Ferguson M, McNicol E, Phalip J, **Evans SR**, Turk DC, Dworkin RH, Rice ASC. Pragmatic trials of pain therapies: a systematic review of methods. *Pain* 163:1: 21-46. 2022.
  20. Ko ER, Henaio R, Frankey K, Petzold EA, Isner PD, Jaehne AK, Allen N, Gardner-Gray J, Hurst G, Pflaum-Carlson J, Jayaprakash N, Rivers EP, Wang H, Ugalde I, Amanullah S, Mercurio L, Chun TH, May L, Hickey RW, Lazarus JE, Gunaratne SH, Pallin DJ, Jambaulikar G, Huckins DS, Ampofo K, Jhaveri R, Jiang Y, Komarow L, **Evans SR**, Ginsburg GS, Tillekeratne LG, McClain MT, Burke TW, Woods CW, Tsalik EL; Antibacterial Resistance Leadership Group. Prospective Validation of a Rapid Host Gene Expression Test to Discriminate Bacterial From Viral Respiratory Infection. *JAMA Netw*



- Open. 2022 Apr 1;5(4):e227299. doi: 10.1001/jamanetworkopen.2022.7299. PMID: 35420659; PMCID: PMC9011121.
21. **Evans SR**, Paraoan D, Perlmutter J, Raman SR, Sheehan JJ, Hallinan ZP. Real-World Data for Planning Eligibility Criteria and Enhancing Recruitment: Recommendations from the Clinical Trials Transformation Initiative. *Therapeutic Innovation & Regulatory Science*. <https://doi.org/10.1007/s43441-020-00248-7>. 2021. May;55(3):545-552.
  22. **Evans SR**. Waking up to p: Comment on “The Role of p-Values in Judging the Strength of Evidence and Realistic Replication Expectations”, *Statistics in Biopharmaceutical Research*, 13:1, 19-21, DOI: 10.1080/19466315.2020.1811151. 2021.
  23. Hamasaki T, Hung HMJ, Hsiao, CF, **Evans SR**. On selecting the critical boundary functions in group-sequential trials with two time-to-event outcomes. *Contemporary Clinical Trials*. <https://doi.org/10.1016/j.cct.2020.106244>. 2021.
  24. Chambers HF, **Evans SR**, Patel R, Cross HR, Harris AD, Doi Y, Boucher HW, van Duin D, Tsalik EL, Holland TL Pettigrew MM, Tamma PD, Hodges KR, Souli M, Fowler Jr VG. Antibacterial Resistance Leadership Group 2.0 – Back to Business. *Clinical Infectious Diseases*, to appear. 2021.
  25. Williams DJ, Creech CB, Walter EB, Martin JM, Gerber JS, Newland JG, Howard L, Hofto ME, Staat MA, Oler RE, Tuyishimire B, Conrad TM, Lee MS, Ghazaryan V, Pettigrew MM, Fowler, Jr. VG, Chambers HF, Zaoutis TE, **Evans SR**, Huskins WC. Short Course Outpatient Antibiotic Therapy for Community-Acquired Pneumonia in Children. *JAMA Pediatrics*, 2022;176(3):253-261. doi:10.1001/jamapediatrics.2021.5547.
  26. Wang M, Earley M, Chen L, Hanson B, Yu Y, Liu Z, Salcedo S, Cober E, Li L, Kanj SS, Gao H, Munita JM, Ordoñez K, Weston G, Satlin M, Valderrama S, Marimuthu K, Stryjewski ME, Komarow L, Luterbach C, Marshall S, Manca C, Paterson DL, Reyes J, Villegas MV, **Evans SR**, Hill C, Arias R, Baum K, Fries BC, Doi Y, Patel R, Kreiswirth BN, Bonomo RA, Chambers HF, Fowler Jr. VG, Arias C, van Duin D. Characteristics of Carbapenem-Resistant *Klebsiella pneumoniae* complex among Patients from Different Global Regions (CRACKLE-2): a Prospective Cohort Study. To appear. *Lancet ID*, 2021.
  27. Kleykamp BA, Dworkin RH, Turke DC, Beaton D, Bhagwagar Z, Burkeh LB, Cowan P, Eccleston C, Ellenberg SS, **Evans SR**, Gewandter JS, Goli V, Farrar JT, Freeman RL, Garrison LP, Iyengar S, Jadad AR, Jensen MP, Junor R, Katz NP, Kesslak JP, Kopecky EA, Lissin D, Markman JD, McDermott MP, Mease PJ, O’Connor AB, Patel KV, Porter K, Raja SN, Rowbotham MC, Sampaio C, Singh JA, Smith SM, Steigerwald I, Strand V, Tive LA, Tobias J, Wasan AD, Wilson AD. Benefit-risk assessment and reporting in clinical trials of chronic pain treatments: IMMPACT Recommendations. To appear. *Pain*, 163:2022:1006–1018.
  28. Johnston SC, Amarenco P, Aunes M, Denison H, **Evans SR**, Himmelmann A, Jahreskog M, James S, Knutsson M, Ladenvall P, Molina CA, Nylander S, Röther J, Wang Y. Ischemic Benefit and Hemorrhagic Risk of Ticagrelor-Aspirin vs. Aspirin in Patients with Acute Ischemic Stroke or TIA. To appear. *Stroke*, 2021.
  29. Wang Y, Pan Y, Li H, Amarenco P, Denison H, **Evans SR**, Himmelmann A, James S, Birve F, Ladenvall P, Molina CA, Johnston SC. Efficacy and safety of ticagrelor and aspirin in moderate ischemic stroke in the THALES trial. To appear. *JAMA Neurology*, 2021.
  30. Jiang Y, Pan Q, Liu Y, **Evans SR**. A Statistical Review: Why Average Weighted Accuracy, not Accuracy or AUC? *Biostatistics and Epidemiology*, 5:2, 267-286, 2021.
  31. Claeys K, Hopkins T, Schlaffer K, Hitchcock S, Jiang Y, **Evans SR**, Johnson J, Leekha S. Comparing the clinical utility of rapid diagnostics for the treatment of Bloodstream Infections using Desirability of Outcome Ranking approach for the Management of Antibiotic Therapy (DOOR-MAT). *Antimicrob Agents Chemother*. 2021 Aug

- 17;65(9):e0044121. doi: 10.1128/AAC.00441-21. Epub 2021 Aug 17. PMID: 34228533; PMCID: PMC8370220.
32. Perez F, Colindres RV, Wilson BM, Saade E, Jump RLP, Banerjee R, Patel R, **Evans SR**, Bonomo RA. The Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT) Reveals Improvements in the Treatment of Bloodstream Infection Caused by *Escherichia coli* and *Klebsiella pneumoniae* in Patients from the Veterans Health Administration. To appear. *Clin Infect Dis*. 2021 Oct 5;73(7):1231-1238. doi: 10.1093/cid/ciab384. PMID: 33978146; PMCID: PMC8492112.
  33. Claeys KC, Schlaffer K, Smith R, Hitchcock S, Jiang Y, **Evans SR**, Johnson JK, Leekha S. Day at the Races: Comparing BioFire FilmArray Blood Culture ID Panels to Verigene Blood Culture in Gram-negative Bloodstream Infections using DOOR-MAT Analysis. To appear. *Clin Infect Dis*. 2021 Sep 15;73(6):1103-1106. doi: 10.1093/cid/ciab262. PMID: 33772269; PMCID: PMC8442774.
  34. Benjamini Y, De Veaux RD, Efron B, **Evans S**, Glickman M, Graubard BI, He X, Meng XL, Reid NM, Stigler SM, Vardeman SB, Wikle CK, Wright T, Young LJ, Kafadar K. ASA President's Task Force Statement on Statistical Significance and Replicability. *The Annals of Applied Statistics*. Vol. 15, No. 3, 1084–1085. <https://doi.org/10.1214/21-AOAS1501>. © Institute of Mathematical Statistics, 2021.
  35. Benjamini Y, De Veaux RD, Efron B, **Evans S**, Glickman M, Graubard BI, He X, Meng XL, Reid NM, Stigler SM, Vardeman SB, Wikle CK, Wright T, Young LJ, Kafadar K. ASA President's Task Force Statement on Statistical Significance and Replicability. *Statistics in Biopharmaceutical Research*. To appear. 2021.
  36. Benjamini Y, De Veaux RD, Efron B, **Evans S**, Glickman M, Graubard BI, He X, Meng XL, Reid NM, Stigler SM, Vardeman SB, Wikle CK, Wright T, Young LJ, Kafadar K. ASA President's Task Force Statement on Statistical Significance and Replicability. *CHANCE*. To appear. 2021.
  37. Benjamini Y, De Veaux RD, Efron B, **Evans S**, Glickman M, Graubard BI, He X, Meng XL, Reid NM, Stigler SM, Vardeman SB, Wikle CK, Wright T, Young LJ, Kafadar K. ASA President's Task Force Statement on Statistical Significance and Replicability. *AmStat News*. To appear. 2021.
  38. Benjamini Y, De Veaux RD, Efron B, **Evans S**, Glickman M, Graubard BI, He X, Meng XL, Reid NM, Stigler SM, Vardeman SB, Wikle CK, Wright T, Young LJ, Kafadar K. ASA President's Task Force Statement on Statistical Significance and Replicability. *Harvard Data Science Review*. <https://hdsr.mitpress.mit.edu/pub/50v12b07/release/1>. 2021.
  39. Montepiedra G, Kim S, Weinberg A, Theron G, Sterling TR, LaCourse SM, Bradford S, Chakhtoura N, Jean-Philippe P, **Evans S**, Gupta A. Using a composite maternal-infant outcome measure in tuberculosis prevention studies among pregnant women. *Clinical Infectious Diseases*, ciaa1674, <https://doi.org/10.1093/cid/ciaa1674>. 2021.
  40. Gewandter JS, McDermott MP, **Evans S**, Katz NP, Markman JD, Simon LS, Turk DC, Dworkin RH. Composite outcomes for pain trials: Considerations for design and interpretation. *Pain*, to appear. 2021.
  41. **Evans SR**, Knutsson M, Amarenco P, Albers GW, Bath PN, Denison H, Ladenvall P, Jonasson J, Easton JD, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC. Methodologies for pragmatic and efficient assessment of benefits and harms: application to the SOCRATES trial. *Clinical Trials*, Vol. 17(6) 617–626, 2020.
  42. Johnston SC, Amarenco P, Denison H, **Evans SR**, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y. Ticagrelor and Aspirin versus Aspirin in Acute Ischemic Stroke or TIA. *N Engl J Medicine*. To appear.
  43. Yin X, Hamasaki T, **Evans SR**. Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS): Design

- Considerations for Selecting the Optimal Treatment. *Statistics in Biopharmaceutical Research*. 2020.
44. Yin X, Hamasaki T, Follmann D, **Evans SR**. OutSMARTing Superbugs. CHANCE, September, 2020.
  45. Wilson BM, Jiang Y, Jump RLP, Colindres RV, Perez F, Bonomo RA, **Evans SR**. Desirability of Outcome Ranking for the Management of Antimicrobial Therapy (DOOR MAT): A Framework for Assessing Antibiotic Selection Strategies in the Presence of Drug Resistance. *CID*, 2021;73(2):344–50. DOI: 10.1093/cid/ciaa1769.
  46. Amarenco P, Denison H, **Evans SR**, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC. Ticagrelor Added to Aspirin in Acute Stroke or TIA in Prevention of Stroke. *JAMA Neurology*. 2020.
  47. Amarenco P, Denison H, **Evans SR**, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC. Ticagrelor Added to Aspirin in Acute Stroke or TIA of Atherosclerotic Origin. *Stroke*. Volume 51, Issue 12, December 2020; Pages 3504-3513. <https://doi.org/10.1161/STROKEAHA.120.032239>.
  48. Dworkin RH, **Evans SR**, Mbowe O, McDermott MP. Essential statistical principles of clinical trials of pain treatments. *Pain Reports*, 2020.
  49. Smith SM, Dworkin RH, Turk DC, McDermott M, Eccleston C, Farrar JT, Rowbotham MC, Bhangwagar Z, Burke LB, Cowan P, Ellenberg SS, **Evans SR**, Freeman RL, Garrison LP, Iyengar S, Jadad A, Jensen MP, Junor R, Kamp C, Katz NP, Kesslak JP, Kopecky EA, Lissin D, Markman JD, Mease PJ, O'Connor AB, Patel KV, Raja SN, Sampaio C, Schoenfeld D, Singh J, Steigerwald I, Strand V, Tive LA, Tobias J, Wasan AD, Wilson HD. Interpretation of chronic pain clinical trial outcomes. *Pain*. 2020.
  50. Krown SE, Moser CB, MacPhail P, et al., Treatment of advanced AIDS-associated Kaposi sarcoma in resource-limited settings: a three-arm, open-label, randomised, non-inferiority trial. *Lancet* 2020; 395: 1195–207.
  51. Proschan M, **Evans SR**. Lead Us Not Into The Temptation of Response-Adaptive Randomization. *Clin Infect Dis.*; Forthcoming.
  52. **Evans SR**, Bigelow R, Chuang-Stein C, Ellenberg S, Gallo P, He W, Jiang Q, Rockhold F. Presenting Risks and Benefits: Helping the Data Monitoring Committee Do Its Job. *Ann Intern Med*. doi:10.7326/M19-1491. 2019.
  53. Liu Y, Tsalik EL, Jiang Y, Ko ER, Woods CW, Henao R, **Evans SR**. Average Weighted Accuracy (AWA): Pragmatic Analysis for a RADICAL Study. *Clin Infect Dis.*; 2020;70(12):2736–42.
  54. **Evans SR**, DeGruttola V. Innovations in Design, Education, and Analysis (IDEA) Introduction. *Clin Infect Dis.*; 2019;68(11):1960.
  55. Asakura K, **Evans SR**, Hamasaki T. Interim Monitoring for Futility in Clinical Trials with Co-primary Endpoints Using Prediction. *Statistics in Biopharmaceutical Research*. Forthcoming.
  56. Follmann D, Fay MP, Hamasaki T, **Evans S**. Analysis of ordered composite endpoints. *Stat Med*. 2020 Feb 28;39(5):602-616. doi: 10.1002/sim.8431. Epub 2019 Dec 19. PMID: 31858640.
  57. Stewart AG, Harris PNA, Chatfield M, **Evans SR**, van Duin D, Patterson DL. Modern clinician-initiated clinical trials to determine optimal therapy for multi-drug resistant Gram-negative infections. *Clin Infect Dis.*; Forthcoming.
  58. van Duin D, Arias CA, Komarow L, Chen L, Hanson B, Weston G, Cober E, Garner OB, Jacob JT, Satlin MJ, Fries BC, Garcia-Diaz J, Doi Y, Dhar S, Kaye KS, Earley M, Hujer AM, Hujer KM, Domitrovic TN, Shropshire W, Dinh A, Manca C, Luterbach C, Wang M, Paterson DL, Banerjee R, Patel R, **Evans S**, Hill C, Arias R, Chambers HF, Fowler Jr VG, Kreiswirth BN, Bonomo RA. Molecular and Clinical Epidemiology of Carbapenem-

- Resistant Enterobacteriaceae. in the United States: a Prospective Cohort Study. *Lancet Infectious Diseases*. 2020 Jun;20(6):731-741. doi: 10.1016/S1473-3099(19)30755-8.
59. Doernberg SB, Komarow L, Tran TTT, Sund Z, Pandori MW, Jensen D, Tsalik EL, Deal CD, Chambers HF, Fowler Jr VG, **Evans SR**, Patel R, Klausner JD. Simultaneous Evaluation of Multiple Diagnostic Assays to Detect *Neisseria gonorrhoea* and *Chlamidia trachomatis* Using a Master Protocol. *Clin Infect Dis.*; Forthcoming.
  60. Miyahara S, Ramchandani R, Kim S, **Evans SR**, Gupta A, Swindells S, Chaisson RE, Montepiedra G. Applying Risk-Benefit Analysis to Outcomes in TB Clinical Trials. *Clin Infect Dis.*; Forthcoming.
  61. Hook EW, Newman L, Drusano G, **Evans SR**, Handsfield HH, Jerse AE, Kong FYS, Lee JW, Taylor SN, Deal C. Development of New Antimicrobials for Urogenital Gonorrhoea Therapy: Clinical Trial Design Considerations. *Clin Infect Dis.*; Forthcoming.
  62. Wunderink RG, Srinivasan A, MD, Barie PS, Chastre J, Dela Cruz CS, Douglas IS, Ecklund M, Evans SE, **Evans SR**, Gerlach AT, Hicks LA, Howell M, Hutchinson ML, Hyzy RC, Kane-Gill SL, Lease ED, Metersky ML, Munro N, Niederman MS, Restrepo M, Sessler CN, Simpson SQ, Swoboda SM, Guillaumet CV, Waterer GW, Weiss CH. Antibiotic Stewardship in the ICU: An Official American Thoracic Society Workshop Report in Collaboration with the American Association of Critical-Care Nurses, American College of Chest Physicians, Centers for Disease Control and Prevention, and Society of Critical Care Medicine. *Annals of the ATS*. Forthcoming.
  63. Adamson PC, Pandori MW, Doernberg SB, Komarow L, Sund Z, Tran TTT, Jensen D, Tsalik EL, Deal CD, Chambers HF, Fowler Jr VG, **Evans SR**, Patel R, Klausner JD. Analytical evaluation of the Abbott RealTime CT/NG Assay for detection of *Chlamydia trachomatis* and *Neisseria gonorrhoeae* in rectal and pharyngeal swabs. *The Journal of Molecular Diagnostics*. Forthcoming.
  64. Henderson H, Luterbach CL, Cober E, Richter SS, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, **Evans S**, Fowler Jr VG., Bonomo RA, Harris A, Napravnik S, van Duin D. The Pitt Bacteremia Score Predicts Mortality in Non-Bacteremic Infections. *Clin Infect Dis.*; Forthcoming.
  65. Johnston SC, Amarenco P, Denison H, **Evans S**, Himmelmann A, James S. The acute Stroke or transient ischemic attack treated with ticagrelor and aspirin for prevention of Stroke and death (THALES) trial: Rationale and design. *Int J Stroke.* ; Forthcoming.
  66. Molina CA, Johnston C, Ladenvall P, Amarenco P, Albers GW, Denison H, Easton DJ, **Evans SR**, Held P, Knutsson M, Minematsu K, Rother J, Wang Y, Wong LKS. Time to Loading Dose and Risk of Recurrent Events in the SOCRATES Trial. *Stroke*. 2019 Mar;50(3):675-682. doi: 10.1161/STROKEAHA.118.022675.
  67. Sugimoto T, Hamasaki T, **Evans SR**, Halabi S. Group-sequential logrank methods for trial designs using bivariate non-competing event-time outcomes. *Lifetime Data Anal.* Forthcoming.
  68. Jiang Y, Follmann D, **Evans SR**. Superbug Clinical Trials. *Wiley StatsRef-Statistics Reference Online*. 2019.
  69. Easton JD, Denison H, **Evans SR**, Knutsson M, Amarenco P, Albers GW, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KL, Johnston SC; SOCRATES Steering Committee and Investigators. Estimated treatment effect of ticagrelor versus aspirin by investigator-assessed events compared with judgement by an independent event adjudication committee in the SOCRATES trial. *Int J Stroke*. 2019 Dec;14(9):908-914.
  70. Lodise Jr TP, Rosenkranz SL, Finnemeyer M, **Evans SR**, Sims M, Zervos MJ, Creech CB, Patel PC, Keefer M, Riska P, Silveira FP, Scheetz M, Wunderink RG, Rodriguez M, Schrank J, Bleasdale SC, Schultz S, Barron M, Stapleton A, Wray D, Chambers HF, Fowler Jr VG, Holland TL. The Emperor's New Clothes: Prospective Observational Evaluation of the Association between Initial Vancomycin Exposure and Failure Rates

- among Adult Hospitalized Patients with MRSA Bloodstream Infections (PROVIDE). *Clin Inf Dis*. 2019 Jun 3. pii: ciz460. doi: 10.1093/cid/ciz460
71. Gewandter JS, Dworkin RH, Turk DC, Devine EG, Hewitt D, Jensen MP, Katz NP, Kirkwood AA, Malamut R, Markman JD, Vrijens B, Allen R, Bujanover S, Burke L, Campbell JN, Carr DB, Conaghan PG, Cowan P, Doyle MK, Edwards RR, **Evans SR**, Farrar JT, Freeman R, Gilron I, Juge D, Kerns RD, Kopecky EA, McDermott MP, Niebler G, Patel KV, Rauck R, Rice ASC, Rowbotham M, Sessler NE, Simon LS, Singla N, Skljarevski V, Tockarshewsky T, Vanhov GF, Wasan AD, Witter J. Improving study conduct and data quality in clinical trials of chronic pain treatments: IMMPACT recommendations. *Journal of Pain*. S1526-5900(19)30880-6. 2019.
  72. **Evans SR**, Follmann D, Liu Y, Holland T, Doernberg SB, Roupheal N, Hamasaki T, Jiang Y, Lok JL, Tran TTT, Harris AD, Fowler, Jr. VG, Boucher H, Kreiswirth BN, Bonomo RA, van Duin D, Paterson DL, Chambers H. Sequential Multiple Assignment Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS). *Clin Infect Dis*. 2019;68(11):1961–7. PMID: 30351426 PMCID: PMC6522685 DOI: 10.1093/cid/ciy912.
  73. **Evans, SR**, Rubin DB, Powers JH, Follmann D. Analysis Populations in Anti-infective Clinical Trials: Whom to Analyze? *Stat Commun Infect Dis*. 2018; NIHMSID 988165
  74. **Evans SR**, Tran TTT, Hujer AM, Hill CB, Hujer KM, Mediavilla JR, Manca C, Domitrovic TN, Perez F, Farmer M, Pitzer KM, Wilson BM, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Fowler Jr VG, Chambers HF, Bonomo RA; Antibacterial Resistance Leadership Group (ARLG). Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam against *Pseudomonas aeruginosa*: PRIMERS IV. *Clin Infect Dis*. 2019;68(11):1823–30. PMID: 30239599 PMC Journal - In Process.
  75. Powers JH, **Evans SR**, Kesselheim AS. Studying new antibiotics for multidrug resistant infections: are today's patients paying for unproved future benefits? *BMJ*. 2018. PMID: 29472192 PMC Journal – In Process
  76. Huskins WC, Fowler Jr VG, **Evans SR**. Adaptive Designs for Clinical Trials: Application to Healthcare Epidemiology Research. *Clin Infect Dis*. 2018; 66(7):1140-46. PMID: 29121202 PMCID: PMC6018921
  77. Van Duin D, Lok JJ, Earley M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, Fowler Jr VG, Paterson DL, Bonomo RA, **Evans SR**. Colistin vs. Ceftazidime-avibactam in the Treatment of Infections due to Carbapenem-Resistant Enterobacteriaceae. *Clin Infect Dis*. 2018; 66(2):163-171. PMID: 29020404 PMCID: PMC5850032
  78. Doernberg SB, Tran TTT, Tong SYC, Paul M, Yahav D, Davis JS, Leibovici L, Boucher HW, Corey GR, Cosgrove SE, Chambers HF, Fowler VG, **Evans SR**, Holland TL. Good studies evaluate the disease while great studies evaluate the patient: Development and application of a Desirability of Outcome Ranking Endpoint for *Staphylococcus Aureus* Bloodstream Infection. *Clin Infect Dis*. 2018. PMID: 30321315 PMC Journal - In Process
  79. Suissa S, Israel E, Donohue J, **Evans SR**, Kemp J. Food and Drug Administration-mandated Trials of Long-Acting  $\beta$ -Agonist Safety in Asthma. Bang for the Buck? *Am J Respir Crit Care Med*. 2018; 197(8):987-990. PMID: 29357261
  80. Wong KSL, Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Himmelmann A, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Johnston SC. Efficacy and Safety of Ticagrelor in Relation to Aspirin Use Within the Week Before Randomization in the SOCRATES Trial. *Stroke*. 2018; 49(7):1678-1685. PMID: 29915123 PMCID: PMC6019568
  81. Gewandter JS, Brell J, Cavaletti G, Dougherty PM, **Evans SR**, Howie L, McDermott MP, O'Mara A, Smith AG, Dastros-Pitei D, Gauthier LR, Haroutounian S, Jarpe M, Katz NP,

- Loprinzi C, Richardson P, Smith EML, Wen PY, Turk DC, Dworkin RH, Freeman R. Trial designs for chemotherapy-induced peripheral neuropathy prevention: ACTION recommendations. *Neurology*. 2018; 91(9): 403-413. PMID: 30054438 PMCID: PMC6133627
82. Luterbach CL, Boshe A, Henderson HI, Cober E, Richter SS, Salata RA, Kalayjian RC, Watkins RR, Hujer AM, Hujer KM, Doi Y, Kaye KS, **Evans SR**, Fowler VG Jr, Bonomo RA, van Duin D. The Role of Trimethoprim/Sulfamethoxazole in the Treatment of Infections Caused by Carbapenem-Resistant Enterobacteriaceae. *Open Forum Infect Dis*. 2018. PMID: 30631796 PMCID: PMC6324543
  83. Akpa O, Miyahara S, Taiwo B, **Evans S**, Berzins B, Robertson K. Similar changes in neuropsychological functioning in English and Spanish speaking HIV patients. *Brain and Behavior*. DOI: 10.1002/brb3.1083. 2018.
  84. Robertson K, Oladeji B, Jiang H, Kumwenda J, Supparatpinyo K, Campbell T, Hakim J, Tripathy S, Hosseinipour M, Marra CM; 5199 study team, Kumarasamy N, **Evans SR**, Vecchio A, La Rosa A, Santos B, Silva MT, Montano S, Kanyama C, Firnhaber C, Price R, Marcus C, Berzins B, Masih R, Laloo U, Sanne I, Yosief S, Walawander A, Nair A, Sacktor N, Hall C; AIDS Clinical Trials Group. HIV-1 and TB Co-infection in Multinational Resource Limited Settings: Increased neurological dysfunction. *Clin Infect Dis*. 2018. PMID: 30137250 PMC Journal – In Process
  85. **Evans SR**, Powers J. Evaluating Anti-Infective Drugs in the Resistant Pathogen Setting: Can we Use External Controls? *Stat Commun Infect Dis*. 2017; 9(1): 20160003. PMID: 28757914 PMCID: PMC5529043
  86. Patel R, Tsalik EL, Petzold E, Fowler Jr. VG, Klausner JD, **Evans SR**. Antibacterial Resistance Leadership Group (ARLG). MASTERMIND: Bringing Microbial Diagnostics to the Clinic. *Clin Infect Dis*. 2017; 64(3):355-360. PMID: 27927867 PMCID: PMC5894935
  87. Huvane J, Komarow L, Hill C, Tran TT, Pereira C, Rosenkranz S, Finnemeyer M, Earley M, Jiang HJ, Wang R, Lok J, **Evans SR**; Statistical and Data Management Center of the Antibacterial Resistance Leadership Group (ARLG). Fundamentals and Catalytic Innovation: The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. *Clin Infect Dis*. 2017; 64(suppl\_1):S18-S23. PMID: 28350899 PMCID: PMC5848245
  88. Chambers HF, Cross HR, **Evans SR**, Kreiswirth BN, Fowler Jr VG; Antibacterial Resistance Leadership Group (ARLG). The Antibacterial Resistance Leadership Group: Progress Report and Work in Progress. *Clin Infect Dis*. 2017; 64(suppl\_1):S3-S7. PMID: 28350896 PMCID: PMC5850447
  89. Manca C, Hill C, Hujer AM, Patel R, **Evans SR**, Bonomo RA, Kreiswirth BN; Laboratory Center of the Antibacterial Resistance Leadership Group (ARLG). Leading Antibacterial Laboratory Research by Integrating Conventional and Innovative Approaches: The Laboratory Center of the Antibacterial Resistance Leadership Group. *Clin Infect Dis*. 2017; 64(suppl\_1):S13-S17. PMID: 28350898 PMCID: PMC5848373
  90. Anderson DJ, Jenkins TC, **Evans SR**, Harris AD, Weinstein RA, Tamma PD, Han JH, Banerjee R, Patel R, Zaoutis T, Lautenbach E. The Role of Stewardship in Addressing Antibacterial Resistance: Stewardship and Infection Control Committee of the Antibacterial Resistance Leadership Group. *Clin Infect Dis*. 2017; 64(suppl\_1):S36-S40. PMID: 28350902 PMCID: PMC5848301
  91. Tsalik EL, Petzold E, Kreiswirth BN, Bonomo RA, Banerjee R, Lautenbach E, **Evans SR**, Hanson KE, Patel R; and the Diagnostics and Devices Committee of the Antibacterial Resistance Leadership Group. Advancing Diagnostics to Address Antibacterial Resistance: The Diagnostics and Devices Committee of the Antibacterial Resistance Leadership

- Group. *Clin Infect Dis*. 2017; 64(suppl\_1):S41-S47. PMID: 28350903 PMCID: PMC5848376
92. Sugimoto T, Hamasaki T, **Evans SR**, Sozu T. Sizing clinical trials when comparing bivariate time-to-event outcomes. *Stat Med*. 2017; 36(9):1363-1382. PMID: 28120524 PMCID: PMC5533151
  93. Hamasaki T, **Evans SR**, Asakura K. Design, data monitoring, and analysis of clinical trials with co-primary endpoints: a review. *J Biopharm Stat*. 2018; 28(1):28-51. PMID: 29083951 PMCID: PMC6135538
  94. Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong L, Johnston SC, SOCRATES Steering Committee and Investigators. Efficacy and safety of ticagrelor versus aspirin in acute stroke or transient ischaemic attack of atherosclerotic origin: a subgroup analysis of SOCRATES, a randomised, double-blind, controlled trial. *Lancet Neurol*. 2017; 16(4):301-310. PMID: 28238711
  95. Gewandter JS, McDermott MP, Kitt RA, Chaudari J, Koch JG, **Evans SR**, Gross RA, Markman JD, Turk DC, Dworkin RH. Interpretation of CIs in clinical trials with non-significant results: systematic review and recommendations. *BMJ Open*. 2017; 7(7):e017288. PMID: 28720618 PMCID: PMC5726092
  96. Celestin AR, Odom SR, Angelidou K, **Evans SR**, Coimbra A, Guidry CA, Cuschieri J, Banton KL, O'Neill PJ, Askari A, Namias N, Duane TM, Claridge JA, Dellinger EP, Sawyer RA, Cook CH. Novel Method Suggests Global Superiority of Short Duration Antibiotics for Intra-abdominal Infections. *Clin Infect Dis*. 2017; 65(9):1577-1579. PMID: 29020201 PMCID: PMC5850039
  97. Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Hill MD, Jonasson J, Kasner SE, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC, SOCRATES Steering Committee and Investigators. Ticagrelor Versus Aspirin in Acute Embolic Stroke of Undetermined Source (ESUS). *Stroke*. 2017; 48(9):2480-2487. PMID: 28720658
  98. Easton JD, Aunes M, Albers GW, Amarenco P, Bokelund-Singh S, Denison H, **Evans SR**, Held P, Jahreskog M, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC; SOCRATES Steering Committee and Investigators. Risk for Major Bleeding in Patients Receiving Ticagrelor Compared With Aspirin After Transient Ischemic Attack or Acute Ischemic Stroke in the SOCRATES Study (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). *Circulation*. 2017; 136(10):907-916. PMID: 28655834
  99. Holland TL, Davis JS, Doernberg SB, Tran TTT, **Evans SR**, Cosgrove SE, Boucher HW, Corey GR, Fowler V, Chambers HF, Tong SYC. Analysis of CAMERA-1 *S. aureus* Bacteremia Trial Results Using the DOOR. *Open Forum Infectious Diseases*. 2017 Jan 1; 4(suppl\_1):s541-s541.
  100. Eilertson B, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, **Evans SR**, Fowler VG Jr, Bonomo RA, DeHovitz J, Kreiswirth B, van Duin D; Antibacterial Resistance Leadership Group. Carbapenem-Resistant Enterobacteriaceae Infections in Patients on Renal Replacement Therapy. *Open Forum Infect Dis*. 2017; 4(4):ofx216. PMID: 29181422 PMCID: PMC5695622
  101. **Evans SR**, Harris AD. Methods and issues in studies of CRE. *Virulence*. 2017; 8(4):453-459. PMID: 27470534 PMCID: PMC5477696
  102. Ochiai T, Hamasaki T, **Evans SR**, Asakura K, Ohno Y. Group-sequential three-arm noninferiority clinical trial designs. *J Biopharm Stat*. 2017; 27(1):1-24. PMID: 26892481. PMCID: PMC4990829.
  103. Wang Y, Minematsu K, Wong KS, Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Jonasson J, Molina CA, Johnston SC. Ticagrelor in Acute Stroke or Transient

- Ischemic Attack in Asian Patients: From the SOCRATES Trial (Acute Stroke or Transient Ischemic Attack Treated With Aspirin or Ticagrelor and Patient Outcomes). *Stroke*. 2017; 48(1):167-173. PMID: 27899747
104. Gewandter JS, Kitt RA, Hunsinger MR, Poku J, Lozano J, Chaudari J, **Evans SR**, Gross RA, McDermott MP, Rowbotham MC, Turk DC, Dworkin RH. Reporting of data and safety monitoring boards (DSMB) in publications of randomized clinical trials is often deficient: An ACTION systematic review and recommendations. *J Clin Epidemiol*. 2017; 83:101-107. PMID: 28126598 PMCID: PMC5780643
  105. Mukherjee PK, Chen H, Patton LL, **Evans SR**, Lee A, Kumwenda J, Hakim J, Masheto G, Sawe F, Pho MT, Freedberg KA, Shiboski CH, Ghannoum MA, Salata RA; Oral HIV/AIDS Research Alliance (OHARA)AIDS Clinical Trials Group (ACTG) 5265 Team. Topical gentian violet compared to nystatin oral suspension for the treatment of oropharyngeal candidiasis in HIV-1 infected participants. *AIDS*. 2017; 31(1):81-88. PMID: 27677161 PMCID: PMC5127761
  106. Asakura K, Hamasaki T, **Evans SR**. Interim evaluation of efficacy or futility in group-sequential trials with multiple co-primary endpoints. *Biom J*. 2017; 59(4):703-731. PMID: 27757980 PMCID: PMC6222168
  107. Rojas LJ, Salim M, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Marshall S, Rudin SD, Domitrovic TN, Hujer AM, Hujer KM, Doi Y, Kaye KS, **Evans SR**, Fowler Jr VG, Bonomo RA, van Duin D. Colistin Resistance in Carbapenem-Resistant *Klebsiella Pneumoniae*: Laboratory Detection and Impact on Mortality. *Clin Infect Dis*. 2017; 64(6):711-718. PMID: 27940944 PMCID: PMC5850634
  108. Adejumo O, Oladeji B, Akpa O, Malee K, Baiyewu O, Ogunniyi A, **Evans SR**, Berzins B, Taiwo B. Psychiatric disorders and adherence to antiretroviral therapy among a population of HIV-infected adults in Nigeria. *Int J STD AIDS*. 2016; 27(11):938-49. PMID: 26384949 PMCID: PMC4798907
  109. **Evans SR**, Hujer AM, Jiang H, Hill CB, Hujer KM, Mediavilla JR, Manca C, Tran TT, Domitrovic TN, Higgins PG, Seifert H, Kreiswirth BN, Patel R, Jacobs MR, Chen L, Sampath R, Hall T, Marzan C, Fowler Jr VG, Chambers HF, Bonomo RA. Informing Antibiotic Treatment Decisions: Evaluating Rapid Molecular Diagnostics to Identify Susceptibility and Resistance to Carbapenems against *Acinetobacter* spp. in PRIMERS III. *J Clin Microbiol*. 2016; 55(1):134-144. PMID: 27795336 PMCID: PMC5228224
  110. Andrews NA, Latremoliere A, Basbaum AI, Mogil JS, Porreca F, Rice ASC, Woolf CJ, Currie GL, Dworkin RH, Eisenach JC, **Evans SR**, Gewandter JS, Gover TD, Handwerker H, Huang W, Iyengar S, Jensen MP, Kennedy JD, Lee N, Levine J, Lidster K, Machin I, McDermott MP, McMahon SB, Price TJ, Ross SE, Scherrer G, Seal RP, Sena ES, Silva E, Stone L, Svensson CI, Turk DC, Whiteside G. Ensuring transparency and minimization of methodologic bias in preclinical pain research: PPRECISE considerations. *Pain*. 2016; 157(4):901-9. PMID: 26683237 PMCID: PMC4794131
  111. **Evans SR**, Follmann D. Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: A Step Toward Pragmatism in Benefit:risk Evaluation. *Stat Biopharm Res*. 2016; 8(4):386-393. PMID: 28435515 PMCID: PMC5394932
  112. **Evans SR**, Pennello G, Pantoja-Galicia N, Jiang H, Hujer AM, Hujer KM, Manca C, Hill C, Jacobs MR, Chen L, Patel R, Kreiswirth BN, Bonomo RA. Benefit-risk Evaluation for Diagnostics: A Framework (BED-FRAME). *Clin Infect Dis*. 2016; 63(6):812-7. PMID: 27193750 PMCID: PMC4996133
  113. Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, **Evans SR**, Held P, Jonasson J, Minematsu K, Molina CA, Wang Y, Wong L; SOCRATES Steering Committee and Investigators. Ticagrelor versus Aspirin in Acute Stroke or Transient Ischemic Attack. *N Engl J Medicine*. 2016; 375(1):35-43. PMID: 27160892



114. Messina JA, Cober E, Richter SS, Perez F, Salata RA, Kalayjian RC, Watkins RR, Scalera NM, Doi Y, Kaye KS, **Evans SR**, Bonomo RA, Folwer Jr. VG, van Duin D; Antibacterial Resistance Leadership Group. Hospital Readmissions in Patients with Carbapenem-Resistant *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol*. 2016; 37(3):281-8. PMID: 26686227 PMCID: PMC4785868
115. Pennello G, Pantoja-Galicia N, **Evans SR**. Comparing diagnostic tests on benefit-risk. *J Biopharm Stat*. 2016; 26(6):1083-1097. PMID: 27548805 PMCID: PMC5471848
116. Montepiedra G, Yuen CM, Rich ML, **Evans SR**. Totality of outcomes: A different paradigm in assessing interventions for treatment of tuberculosis. *J Clin Tuberc Other Mycobact Dis*. 2016; 4:9-13. PMID: 28042610 PMCID: PMC5193477
117. Wen S, He W, **Evans SR**, Quartey G, Norton JD, Chuang-Stein C, Jiang Q, Ma H, Bhattacharya M. Practical Analysis and Visualization Tools for Benefit-Risk Assessment in Drug Development: A Review of Recent FDA Advisory Committee Meeting Packages. *Stat Biopharm Res*. 2016; 8(4):409-16.
118. Ma H, Jiang Q, Chuang-Stein C, **Evans SR**, He W, Quartey G, Scott J, We S, Arani R. Considerations on Endpoint Selection, Weighting Determination, and Uncertainty Evaluation in the Benefit-Risk Assessment of Medical Product. *Stat Biopharm Res*. 2016; 8(4):417-25.
119. Robertson K, Jiang H, **Evans SR**, Marra CM, Berzins B, Hakim J, Sacktor N, Silva MT, Campbell TB, Nair A, Schouten J; 5271 study team, Kumwenda J, Supparatpinyo K, Tripathy S, Kumarasamy N, la Rosa A, Montano S, Mwafongo A, Firnhaber C, Sanne I, Naini L, Amod F, Walawander A; AIDS Clinical Trials Group. International neurocognitive normative study: neurocognitive comparison data in diverse resource-limited settings: AIDS Clinical Trials Group A5271. *J Neurovirol*. 2016; 22(4):472-8. PMID: 26733457 PMCID: PMC4981921
120. Hauck C, Cober E, Richter S, Perez F, Salata R, Kalayjian RC, Watkins RR, Scalera NM, Doi Y, Kaye KS, **Evans SR**, Fowler VG Jr, Bonomo RA, van Duin D. Spectrum of Excess Mortality due to Carbapenem-Resistant *Klebsiella pneumoniae* Infections. *Clin Microbiol Infect*. 2016; 22(6):513-9. PMID: 26850824 PMCID: PMC4930369
121. Huntington Study Group, Frank S, Testa CM, Stamler D, Kayson E, Davis C, Edmondson MC, Kinel S, Leavitt B, Oakes D, O'Neill C, Vaughan C, Goldstein J, Herzog M, Snively V, Whaley J, Wong C, Suter G, Jankovic J, Jimenez-Shahed J, Hunter C, Claassen DO, Roman OC, Sung V, Smith J, Janicki S, Clouse R, Saint-Hilaire M, Hohler A, Turpin D, James RC, Rodriguez R, Rizer K, Anderson KE, Heller H, Carlson A, Criswell S, Racette BA, Revilla FJ, Nucifora F Jr, Margolis RL, Ong M, Mendis T, Mendis N, Singer C, Quesada M, Paulsen JS, Brashers-Krug T, Miller A, Kerr J, Dubinsky RM, Gray C, Factor SA, Sperin E, Molho E, Eglow M, Evans S, Kumar R, Reeves C, Samii A, Chouinard S, Beland M, Scott BL, Hickey PT, Esmail S, Fung WL, Gibbons C, Qi L, Colcher A, Hackmyer C, McGarry A, Klos K, Gudesblatt M, Fafard L, Graffitti L, Schneider DP, Dhall R, Wojcieszek JM, LaFaver K, Duker A, Neefus E, Wilson-Perez H, Shprecher D, Wall P, Blindauer KA, Wheeler L, Boyd JT, Houston E, Farbman ES, Agarwal P, Eberly SW, Watts A, Tariot PN, Feigin A, **Evans S**, Beck C, Orme C, Edicola J, Christopher E. Effect of Deutetrabenazine on Chorea Among Patients With Huntington Disease: A Randomized Clinical Trial. *JAMA*. 2016; 316(1):40-50. PMID: 27380342
122. **Evans SR**, Hujer AM, Jiang H, Hujer KM, Hall T, Marzan C, Jacobs MR, Sampath R, Ecker DJ, Manca C, Chavda K, Zhang P, Fernandez H, Chen L, Mediavilla JR, Hill CB, Perez F, Caliendo AM, Fowler Jr. VG, Chambers HF, Kreiswirth BN, and Bonomo RA; Antibacterial Resistance Leadership Group. Rapid Molecular Diagnostics, Antibiotic Treatment Decisions, and Developing Approaches to Inform Empiric Therapy: PRIMERS I and II. *Clin Infect Dis*. 2016; 62(2):181-9. PMID: 26409063 PMCID: PMC4690483

123. **Evans SR**, Follmann D. Comment: Fundamentals and Innovation in Antibiotic Trials. *Stat Biopharm Res.* 2015; 7(4):331-336. PMID: 27087893 PMCID: PMC4831648
124. **Evans SR**, Rubin D, Follmann D, Pennello G, Huskins WC, Powers JH, Schoenfeld D, Chuang-Stein C, Cosgrove SE, Fowler Jr. VG, Lautenbach E, Chambers HF. Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR). *Clin Infect Dis.* 2015; 61(5):800-6. PMID: 26113652 PMCID: PMC4542892
125. Uno H, Wittes J, Fu H, Solomon SD, Claggett B, Tian L, Cai T, Pfeffer MA, **Evans SR**, Wei LJ. Alternatives to hazard ratios for comparing efficacy or safety of therapies in noninferiority studies. *Ann Intern Med.* 2015; 163:127-134. PMID: 26054047 PMCID: PMC4510023.
126. Dorsey R. and the Huntington Study Group REACH2HD Investigators. Safety, tolerability, and efficacy of PBT2 in Huntington disease: a phase 2, randomised, double-blind, placebo-controlled trial. *Lancet Neurol.* 2015; 14(1):39-47. PMID: 25467848
127. Ando Y, Hamasaki T, **Evans SR**, Asakura K, Sugimoto T, Sozu T, Ohno Y. Sample size considerations in clinical trials when comparing two interventions using multiple co-primary binary relative risk contrasts. *Stat Biopharm Res.* 2015; 7(2):81-94. PMID: 26167243 PMCID: PMC4497828.
128. Hamasaki T, Asakura K, **Evans SR**, Sugimoto T, Suzo T. Group-sequential Strategies in Clinical Trials with Multiple Co-primary Outcomes. *Stat Biopharm Res.* 2015; 7(1):36-54. PMID: 25844122 PMCID: PMC4382106.
129. van Duin D, Cober E, Richter SS, Perez F, Kalayjian RC, Salata RA, **Evans SR**, Fowler Jr. VG, Kaye KS, Bonomo R. Impact of Therapy and Strain Type on Outcomes in Urinary Tract Infections Caused by Carbapenem-Resistant *Klebsiella pneumoniae*. *J Antimicrob Chemother.* 2015; 70(4):1203-11. PMID: 25492391 PMCID: PMC4356203
130. van Duin D, Cober E, Richter S, Perez F, Kalayjian RC, Salata RA, **Evans SR**, Fowler Jr. VG, Bonomo RA, Kaye KS. Residence in Skilled Nursing Facilities is Associated with Tigecycline Non-Susceptibility in Carbapenem-Resistant *Klebsiella pneumoniae*. *Infect Control Hosp Epidemiol.* 2015; 36(8):942-8. PMID: 25990806 PMCID: PMC4642723
131. Lee AJ, Bosch RJ, **Evans SR**, Wu K, Harrison T, Grant P, Clifford DB. Patterns of peripheral neuropathy in ART-naïve patients initiating modern ART regimen. *J Neurovirol.* 2015; 21(2):210-8. PMID: 25678143 PMCID: PMC4624403
132. Shiboski CH, Chen H, Secours R, Lee A, Webster-Cyriaque J, Ghannoum M, **Evans SR**, Bernard D, Reznik D, Dittmer DP, Hosey L, Sévère P, Aberg JA; Oral HIV/AIDS Research Alliance, Subcommittee of the AIDS Clinical Trial Group. High accuracy of common HIV-related oral disease diagnoses by non-oral health specialists in the AIDS Clinical Trial Group. *PLoS One.* 2015; 10(7):e0131001. PMID: 26148192 PMCID: PMC4492974
133. Asakura K, Hamasaki T, Sugimoto T, Hayashi K, **Evans SR**, Sozu T. Sample size determination in group-sequential clinical trials with two co-primary endpoints. *Stat Med.* 2014; 33(17):2897-913. PMID: 24676799 PMCID: PMC4082481
134. Chambers HF, Bartlett JG, Bonomo RA, Cosgrove S, Cross HR, Daum RS, **Evans SR**, Knisely J, Kreiswirth BN, Lautenbach E, Mickley BS, Patel R, Pettigrew MM, Rodvold K, Spellberg B, Fowler Jr. VG. Antibacterial Resistance Leadership Group: Open for Business. *Clin Infect Dis.* 2014; 58(11):1571-6. PMID: 24610430 PMCID: PMC4017892
135. Stafford KA, Boutin M, **Evans SR**, Harris AD. Difficulties in demonstrating superiority of an antibiotic for multi-drug resistant bacteria in non-randomized studies. *Clin Infect Dis.* 2014; 59(8):1142-7. PMID: 24982037 PMCID: PMC4271096
136. van Duin D, Cober ED, Richter SS, Perez F, Cline M, Kaye KS, Kalayjian RC, Salata RA, **Evans SR**, Fowler Jr. VG, Bonomo RA. Tigecycline Therapy for Carbapenem-Resistant *Klebsiella pneumoniae* (CRKP) Bacteriuria Leads to Tigecycline Resistance. *Clin Microbiol Infect.* 2014; 20(12):O1117-20. PMID: 24931918 PMCID: PMC4265572

137. van Duin D, Perez F, Rudin SD, Cober E, Hanrahan J, Ziegler J, Webber R, Fox J, Mason P, Richter SS, Cline M, Hall GS, Kaye KS, Jacobs MR, Kalayjian RC, Salata RA, Segre JA, Conlan S, **Evans SR**, Fowler Jr. VG, Bonomo RA. Surveillance of Carbapenem-Resistant *Klebsiella pneumoniae*: Tracking Molecular Epidemiology and Outcomes through a Regional Network. *Antimicrob Agents Chemother.* 2014; 58(7):4035-41. PMID: 24798270 PMID: PMC4068524
138. Shiboski CH, Chen H, Ghannoum MA, Komarow L, **Evans SR**, Mukherjee PK, Isham N, Katzenstein D, Asmelash A, Omozoarhe AE, Gengiah S, Allen R, Tripathy S, Swindells S. Role of Oral Candidiasis in Tuberculosis and HIV co-Infection: AIDS Clinical Trial Group Protocol A5253. *Int J Tuberc Lung Dis.* 2014; 18(6):682-8. PMID: 24903939 PMID: PMC4157598
139. Kalayjian RC, Wu K, **Evans SR**, Clifford DB, Pallaki M, Currier JS, Smurzynski M. Proteinuria is Associated with Neurocognitive Impairment in Antiretroviral Therapy Treated HIV-infected Individuals. *J Acquir Immune Defic Syndr.* 2014; 67(1):30-5. PMID: 25118793 PMID: PMC4133749
140. Sacktor N, Miyahara S, **Evans SR**, Schifitto G, Cohen B, Haughey N, Drewes JL, Graham D, Zink MC, Anderson C, Nath A, Pardo CA, McCarthy S, Hosey L, Clifford D; ACTG A5235 team. Impact of minocycline on cerebrospinal fluid markers of oxidative stress, neuronal injury, and inflammation in HIV-seropositive individuals with cognitive impairment. *J Neurovirol.* 2014; 20(6):620-6. PMID: 25377444 PMID: PMC4268406
141. Sugimoto T, Sozu T, Hamasaki T, **Evans SR**. A Logrank Test-Based Method for Sizing Clinical Trials with Two Co-Primary Time-to-Event Endpoints. *Biostatistics.* 2013; 14(3):409-21. PMID: 23307913 PMID: PMC4148615
142. Hamasaki T, **Evans SR**. Noninferiority Clinical Trials: Issues in Design, Monitoring, Analyses, and Reporting. *Igaku no Ayumi (Japanese) Translation: Int J Clin Exp Med.* 2013; 244(13):1212-16.
143. Hamasaki T, Sugimoto T, **Evans SR**, Sozu T. Sample Size Determination for Clinical Trials with Co-Primary Outcomes: Exponential Event-Times. *Pharm Stat.* 2013; 12(1):28-34. PMID: 23081932 PMID: PMC3770150
144. Harrison T, Miyahara S, Lee A, **Evans SR**, Bastow B, Simpson D, Gilron I, Dworkin R, Daar ES, Wieclaw L, Clifford DB. Experience and Challenges Presented by a Multicenter Crossover Study of Combination Analgesic Therapy for the Treatment of Painful HIV-Associated Polyneuropathies. *Pain Med.* 2013; 14(7):1039-47. PMID: 23565581 PMID: PMC4207215
145. Ghannoum MA, Mukherjee PK, Warshaw EM, **Evans SR**, Korman NJ, Tavakkol A. Molecular Analysis of Dermatophytes Suggests Spread of Infection among Household Members. *Cutis.* 2013; 91(5):237-45. PMID: 23772429
146. Chen H, Clifford DB, Deng L, Wu K, Lee AJ, Bosch R, Riddler SA, Ellis RJ, **Evans SR**. Peripheral Neuropathy in ART-Experienced Patients: Prevalence and Risk Factors. *J Neurovirol.* 2013; 19(6):557-64. PMID: 24297499 PMID: PMC3965352
147. Nakasujja N, Miyahara S, Evans SR, Lee A, Musisi S, Katabira E, Robertson K, Ronald A, Clifford DB, Sacktor N. A randomized trial of minocycline in the treatment of HIV-associated cognitive impairment. *Neurology.* 2013; 80:196-202. PMID: 23269596 PMID: PMC3589188
148. **Evans SR**, Lee AJ, Ellis RJ, Chen H, Wu K, Bosch RJ, Clifford DB. HIV Peripheral Neuropathy Progression: Protection with Glucose-Lowering Drugs? *J Neurovirol.* 2012; 18(5):428-33. PMID: 22806348 PMID: PMC3485691
149. Robertson K, Jiang H, Kumwenda J, Supparatpinyo K, **Evans SR**, Campbell TB, Price R, Tripathy S, Kumarasamy N, La Rosa A, Santos B; 5199 study team, Silva MT, Montano S, Kanyama C, Faesen S, Murphy R, Hall C, Marra CM, Marcus C, Berzins B, Allen R, Housseinipour M, Amod F, Sanne I, Hakim J, Walawander A, Nair A; AIDS Clinical Trials

- Group. Improved Neuropsychological and neurological functioning across three antiretroviral regimens in diverse resource-limited settings: AIDS Clinical Trials Group Study A5199, the International Neurological Study. *Clin Infect Dis*. 2012; 55(6):868-76. PMID: 22661489 PMCID: PMC3491853
150. **Evans SR**, Ellis RJ, Chen H, Yeh TM, Lee AJ, Schifitto G, Wu K, Bosch RJ, McArthur JC, Simpson DM, Clifford DB. Peripheral Neuropathy in HIV: Prevalence and Risk Factors. *AIDS*. 2011; 25(7):919-28. PMID: 21330902 PMCID: PMC3196556
  151. Sacktor N, Miyahara S, Deng L, **Evans SR**, Schifitto G, Cohen BA, Paul R, Robertson K, Jarocki B, Scarsi K, Coombs RW, Zink MC, Nath A, Smith E, Ellis RJ, Singer E, Weihe J, McCarthy S, Hosey L, Clifford DB; ACTG A5235 team. Minocycline Treatment for HIV-Associated Cognitive Impairment: Results from a Randomized Trial. *Neurology*. 2011; 77(12):1135-42. PMID: 21900636 PMCID: PMC3174065
  152. Schifitto G, Deng L, Yeh TM, **Evans SR**, Ernst T, Zhong J, Clifford DB. Clinical, Laboratory, and Neuroimaging Characteristics of Fatigue in HIV-infected Individuals. *J Neurovirol*. 2011; 17(1):17-25. PMID: 21181521 PMCID: PMC3229167
  153. Robertson K, Kumwenda J, Supparatpinyo K, Jiang JH, Evans S, Campbell TB, Price RW, Murphy R, Hall C, Marra CM, Marcus C, Berzins B, Masih R, Santos B, Silva MT, Kumarasamy N, Walawander A, Nair A, Tripathy S, Kanyama C, Hosseinipour M, Montano S, La Rosa A, Amod F, Sanne I, Firnhaber C, Hakim J, Brouwers P; AIDS Clinical Trials Group. A Multinational Study of Neurological Performance in Antiretroviral Therapy-Naïve HIV-1-Infected Persons in Diverse Resource-Constrained Settings. *J Neurovirol*. 2011; 17(5):438-47. PMID: 21786076 PMCID: PMC3362044
  154. Smurzynski M, Wu K, Letendre S, Robertson K, Bosch RJ, Clifford DB, **Evans SR**, Collier AC, Taylor M, Ellis R. Effects of Central Nervous System Antiretroviral Penetration on Cognitive Functioning in the ALLRT Cohort. *AIDS*. 2011; 25(3):357-65. PMID: 21124201 PMCID: PMC3022370
  155. **Evans SR**. Fundamentals of Clinical Trial Design. *J Exp Stroke Transl Med*. 2010; 3(1):19-27. PMID: 21533012 PMCID: PMC3083073
  156. **Evans SR**. Clinical Trial Structures. *J Exp Stroke Transl Med*. 2010; 3(1):8-18. PMID: 21423788 PMCID: PMC3059315
  157. **Evans SR**. Common Statistical Concerns in Clinical Trials. *J Exp Stroke Transl Med*. 2010; 3(1):1-7. PMID: 21423790 PMCID: PMC3059317
  158. **Evans SR**. Estudos Clinicos de Nao-Inferioridade. *Revista Brasileira de Medicina*. 2010; 3(1):1-7.
  159. Yeh TM, **Evans SR**, Gulick RM, Clifford DB. Vicriviroc and Peripheral Neuropathy: Results from ACTG 5211. *HIV Clin Trials*. 2010; 11(1):51-8. PMID: 20400411 PMCID: PMC2958041
  160. Zhao Y, Navia BA, Marra CM, Singer EJ, Chang L, Berger J, Ellis RJ, Kolson DL, Simpson D, Miller EN, Lipton SA, **Evans SR**, Shifitto G; Adult Aids Clinical Trial Group (ACTG) 301 Team. Memantine for AIDS Dementia Complex: Open-label Report of ACTG 301. *HIV Clin Trials*. 2010; 11(1):59-67. PMID: 20400412 PMCID: PMC2981797
  161. Fichtenbaum CJ, Yeh TM, **Evans SR**, Aberg JA. Treatment with Pravastatin and Fenofibrate Improves Atherogenic Lipid Profiles but not Inflammatory Markers in ACTG 5087. *J Clin Lipidol*. 2010; 4(4):279-87. PMID: 20824151 PMCID: PMC2932453
  162. Glickman M, **Evans SR**. The 2009 New England Symposium on Statistics in Sports. *Journal of Quantitative Analysis in Sports*. 2010; 6(2):13.
  163. Robertson KR, Su Z, Margolis DM, Krambrink A, Havlir DV, **Evans SR**, Skiest DJ; A5170 Study Team. Neurocognitive Effects of Treatment Interruption in Stable HIV-Positive Patients in an Observational Cohort. *Neurology*. 2010; 74(16):1260-6. PMID: 20237308 PMCID: PMC2860482
  164. **Evans SR**. Noninferiority Clinical Trials. *Chance*. 2009; 22(3):53-58

165. Li L, **Evans SR**, Uno H, Wei LJ. Predicted Interval Plots (PIPS): A Graphical Tool for Data Monitoring in Clinical Trials. *Stat Biopharm Res.* 2009; 1(4):348-355. PMID: 21423789 PMCID: PMC3059316
166. Tebas P, Zhang J, Hafner R, Tashima K, Shevits A, Yarasheski K, Berzins B, Owens S, Forand J, **Evans SR**, Murphy R. Peripheral and Visceral Fat Changes Following a Treatment Switch to a Nonthymidine Analog or Nucleoside-sparing Regimen in HIV-Infected Subjects with Peripheral Lipoatrophy: Results of ACTG A5110. *J Antimicrob Chemother.* 2009; 63(5):998-1005. PMID: 19299471 PMCID: PMC2721697
167. Marra CM, Zhao Y, Clifford DB, Letendre S, Evans S, Henry K, Ellis RJ, Rodriguez B, Coombs RW, Schifitto G, McArthur JC, Robertson K; AIDS Clinical Trials Group 736 Study Team. Impact of combination antiretroviral therapy on cerebrospinal fluid HIV RNA and neurocognitive performance. *AIDS.* 2009; 23(11):1359-66. PMID: 19424052 PMCID: PMC2706549
168. Valcour V, Yeh TM, Bartt R, Clifford DB, Gerschenson M, **Evans SR**, Cohen BA, Ebenezer GJ, Hauer P, Millar L, Gould M, Tran P, Shikuma C, Souza S, McArthur JC; AIDS Clinical Trials Group (ACTG) 5157 protocol team. Acetyl-L-Carnitine and NRTI-associated neuropathy in HIV-infection. *HIV Med.* 2009; 10(2):103-10. PMID: 19200173 PMCID: PMC2653263
169. **Evans SR**. Benefit:Risk Evaluation in Clinical Trials. *Drug Information Journal.* 2008; 42(3):221.
170. **Evans SR**, Glickman. New England Symposium on Statistics in Sports. *Journal of Quantitative Analysis in Sports.* 2008; 4(2): Article 1.
171. **Evans SR**, Clifford DB, Kitch DW, Goodkin K, Schifitto G, McArthur JC, Simpson DM. Simplification of the Research Diagnosis of HIV-Associated Sensory Neuropathy. *HIV Clin Trials.* 2008; 9(6):434-9. PMID: 19203909 PMCID: PMC2684847
172. Robertson K, Kopinsky K, Hakim J, Merry C, Nakasujja N, Hall C, Traore M, Sacktor N, Clifford D, Newton C, Van Rie A, Holding P, Clements J, Zink C, Mielke J, Hosseinipour M, Lalloo U, Amod F, Marra C, **Evans SR**, Liner J; Second Assessment of NeuroAIDS in Africa Conference Participants. Second Assessment of NeuroAIDS in Africa. *J Neurovirol.* 2008; 14(2):87-101. PMID: 18370346 PMCID: PMC2755561
173. **Evans SR**, Li L, Wei LJ. Data Monitoring in Clinical Trials Using Prediction. *Drug Inf J.* 2007; 41(6):733-742.
174. **Evans SR**, Fichtenbaum CJ, Aberg JA; A5087 Study Team. Comparison of Direct and Indirect Measurement of LDL-C in HIV Infected Individuals: ACTG 5087. *HIV Clin Trials.* 2007; 8(1):45-52. PMID: 17434848 PMCID: PMC2288650
175. **Evans SR**. When and How Can Endpoints Be Changed After Initiation of a Randomized Clinical Trial? *PLoS Clin Trials.* 2007; 2(4):e18. PMID: 17443237 PMCID: PMC1852589
176. **Evans SR**, Simpson DM, Kitch DW, King A, Clifford DB, Cohen BA, McArthur JC; Neurologic AIDS Research Consortium; AIDS Clinical Trials Group. A Randomized Trial Evaluating Prosaptide™ for HIV-Associated Sensory Neuropathies: Use of an Electronic Diary to Record Neuropathic Pain. *PLoS One.* 2007; 2(6):e551. PMID: 17653259 PMCID: PMC1919427
177. **Evans SR**, Yeh TM, Sacktor N, Clifford DB, Simpson D, Miller EN, Ellis RJ, Valcour V, Marra CM, Millar L, Shifitto G; AIDS Clinical Trials Group and the Neurologic AIDS Research Consortium. Selegiline Transdermal System (STS) for HIV-Associated Neurocognitive Impairment: Open-label Report of ACTG 5090. *HIV Clin Trials.* 2007; 8(6):437-46. PMID: 18042509
178. **Evans SR**, Wang R, Haija R, Zhang J, Rajicic N, Xanthakis V, Peeples L, Anderson J, Sinha S. Evaluation of Distance Learning in an Introduction to Biostatistics Course. *Statistical Education Research Journal.* 2007; 6(2):59-77.

179. Clifford DB, Mitike MT, Mekonnen Y, Zhang J, Zenebe G, Melaku Z, Zewde A, Gessesse N, Wolday D, Messele T, Teshome M, **Evans SR**. Neurological Evaluation of Untreated HIV Infected Adults in Ethiopia. *J Neurovirol.* 2007; 13(1):67-72. PMID: 17454450
180. Schifitto G, Zhang J, **Evans SR**, Sacktor N, Simpson D, Millar LL, Hung VL, Miller EN, Smith E, Ellis RJ, Valcour V, Singer E, Marra C, Kolson D, Weihe J, Rimmel R, Katzenstein D, Clifford DB; ACTG A5090 Team. A multicenter trial of selegiline transdermal system for HIV-associated cognitive impairment. *Neurology.* 2007; 69(13):1314-1321. PMID: 17652642
181. Zhou L, Kitch DW, **Evans SR**, Raman S, Hauer P, Ebenezer GJ, Gerschenson M, Marra CM, Valcour V, Diaz-Arrastia R, Goodkin K, Millar L, Shriver S, Asmuth DM, Clifford DB, Simpson DM, McArthur JC; NARC and ACTG A5117 Study Group. Correlates of Epidermal Nerve Fiber Densities in HIV-associated Distal Sensory Polyneuropathy. *Neurology.* 2007; 68(24):2113-9. PMID: 17562831
182. Tebas P, Zhang J, Yarasheski K, **Evans SR**, Fischl MA, Shevitz A, Feinberg J, Collier AC, Shikuma C, Brizz B, Sattler F; AIDS Clinical Trials Group (ACTG). Switching to a protease inhibitor-containing, nucleoside-sparing regimen (lopinavir/ritonavir plus efavirenz) increases limb fat but raises serum lipid levels: results of a prospective randomized trial (AIDS clinical trial group 5125s). ACTG 5125s. *J Acquir Immune Defic Syndr.* 2007; 45(2):193-200. PMID: 17527093 PMCID: PMC4441526
183. Robertson KR, Smurzynski M, Parsons TD, Wu K, Bosch RJ, Wu J, McArthur JC, Collier AC, **Evans SR**, Ellis RJ. The Prevalence and Incidence of Neurocognitive Impairment in Patients in the HAART Era. *AIDS.* 2007; 21(14):1915-21. PMID: 17721099
184. Simpson DM, Kitch D, **Evans SR**, McArthur JC, Asmuth DM, Cohen B, Goodkin K, Gerschenson M, Shikuma C, Weihe J, So Y, Marra CM, Diaz-Arrastia, R, Millar L, Shriver S, Clifford DB; ACTG A5117 Study Group. HIV Neuropathy Natural History Cohort Study: Assessment Measures and Risk Factors. *Neurology.* 2006; 66(11):1679-87. PMID: 16769940
185. **Evans SR**, Li L. A Comparison of Goodness of Fit Tests for the Logistic GEE Model. *Stat Med.* 2005; 24(8):1245-61. PMID: 15580592
186. Clifford DB, **Evans SR**, Yang Y, Gulick RM. The Neuropsychological and Neurological Impact of HCV Co-Infection in HIV-Infected Subjects. *AIDS.* 2005; 19 Suppl 3:S64-71. PMID: 16251830
187. Ellis R, **Evans SR**, Clifford DB, Moo LR, McArthur JC, Collier AC, Benson C, Bosch R, Simpson D, Yiannoutsos CT, Yang Y, Robertson K; Neurological AIDS Research Consortium; AIDS Clinical Trials Group Study Teams A5001 and A362. Clinical Validation of the NeuroScreen. *J Neurovirol.* 2005; 11(6):503-11. PMID: 16338744
188. Clifford DB, **Evans SR**, Yang Y, Acosta EP, Goodkin K, Tashima K, Simpson D, Dorfman D, Ribaud H, Gulick RM. Long-term Impact of Efavirenz on Neuropsychological Performance and Symptoms in HIV-Infected Individuals. *Ann Intern Med.* 2005; 143(10):714-21. PMID: 16287792
189. Clifford D, Yang Y, **Evans SR**. Neurologic Consequences of Hepatitis C and Human Immunodeficiency Virus Co-Infection. *J Neurovirol.* 2005; 11 Suppl 3:67-71. PMID: 16540458
190. Lopate G, Pestronk A, **Evans SR**, Li L, Clifford D. Anti-sulfatide antibodies in HIV-infected individuals with sensory neuropathy. *Neurology.* 2005; 64(9):1632-4. PMID: 15883332
191. Aberg JA, Zackin RA, Brobst SW, **Evans SR**, Alston BL, Henry WK, Glesby MJ, Torriani FJ, Yang Y, Owens SI, Fichtenbaum CJ; ACTG 5087 Study Team. A Randomized Trial of the Efficacy and Safety of Fenofibrate Versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities: AIDS Clinical Trials Group Study 5087. *AIDS Res Hum Retroviruses.* 2005; 21(9):757-67. PMID: 16218799

192. D'Amico R, Yang Y, Mildvan D, **Evans SR**, Schnizlein-Bick CT, Hafner R, Webb N, Basar M, Zackin R, Jacobson MA. Lower CD4+ T Lymphocyte Nadirs May Indicate Limited Immune Reconstitution in HIV-1 Infected Individuals on Potent Antiretroviral Therapy: Analysis of Immunophenotypic Marker Results of ACTG 5067. *J Clin Immunol*. 2005; 25(2):106-15. PMID: 15821887
193. Osman MA, **Evans SR**. Time Series Analysis of the Somalian Export Demand Equations: A Cointegration Approach. *Journal of Economic and Social Research*. 2005; 4(2):71-92.
194. **Evans SR**, Hosmer DW. Goodness of Fit Tests for Mixed Effects Logistic Models Characterized by Clustering. *Commun Stat Theory Methods*. 2004; 33(5):1139-1155.
195. **Evans SR**, Hosmer DW. Goodness of Fit Tests for Logistic GEE Models: Simulation Results. *Commun Stat Simul Comput*. 2004; 33(1):247-258.
196. Wohl DA, Pilcher CD, **Evans SR**, Revuelta M, McComsey G, Yang Y, Zackin R, Alston B, Welch S, Basar M, Kashuba A, Kondo P, Martinez A, Giardini J, Quinn J, Littles M, Wingfield H, Koletar SL. Absence of Sustained Hyperlactatemia Among HIV-Infected Patients with Risk Factors for Mitochondrial Toxicity. *J Acquir Immune Defic Syndr*. 2004; 35(3):274-8. PMID: 15076242
197. Simpson D, Estanislao L, **Evans SR**, McArthur J, Marcus K, Truufa M, Lucey B, Naismith R, Lonergan T, Clifford D. HIV-Associated Neuromuscular Weakness Syndrome. *AIDS*. 2004; 18(10):1403-12. PMID: 15199316
198. Shikuma CM, Zackin R, Sattler F, Mildvan D, Nyangweso P, Alston B, **Evans SR**, Mulligan K; AIDS Clinical Trial Group 892 Team. Changes in Weight and Lean Body Mass during Highly Active Anti-Retroviral Therapy. *Clin Infect Dis*. 2004; 39(8):1223-30. PMID: 15486848
199. **Evans SR**, Krown SE, Testa MA, Cooley TP, Von Roenn JH. A Phase II Evaluation of Low-Dose Oral Etoposide for the Treatment of Relapsed or Progressive AIDS-Related Kaposi's Sarcoma: An ACTG Clinical Study. *J Clin Oncol*. 2002; 20(15):3236-41. PMID: 12149296
200. Swindells S, **Evans SR**, Zackin R, Goldman M, Haubrich R, Filler SG, Balfour Jr HH. Predictive Value of HIV-1 Viral Load on Risk for Opportunistic Infection. *J Acquir Immune Defic Syndr*. 2002; 30(2):154-8. PMID: 12045677
201. Chung RT, **Evans SR**, Yang Y, Dickens T, Valdez H, Clark R, Shikuma C, Nevin T, Sherman KE. Immune Recovery is Associated with Persistent Rise in HCV RNA, Infrequent Liver Test Flares, and is Not Impaired by HCV in Co-infected Subjects. *AIDS*. 2002; 16(14):1915-23. PMID: 12351951
202. Buonaccorsi JP, Elkinton JS, **Evans SR**, Liebhold AM. Measuring and Testing for Spatial Synchrony. *Ecology*. 2001; 82(6):1668-79.

#### Articles in Non-Refereed Journals

1. Hamasaki T, Asakura K, **Evans SR**, Sugimoto T. Sample Size Modification in Group Sequential Clinical Trials with Co-Primary Endpoints. *Proceedings of the 2013 IASC Satellite for the ISI WSC and the 8th IASC-ARS Conference*. 2013.
2. **Evans SR**, Li L, Wei L. Data Monitoring in Clinical Trials Using Prediction for Data Monitoring of Clinical Trials. *ASA Proceedings of the JSM*, 2007.
3. Osman MA, **Evans SR**. International Demand of Somalia's Livestock Exports: An Error Correction Approach. *Proceedings of Theory and Policy in the Information Age*, 2005.
4. **Evans SR**, Li L. Evaluation of Goodness of Fit Tests for the Logistic GEE Model. *ASA Proceedings of the JSM*, 330-337, 2004.

#### Chapters in Books

1. Levitan B, DiSantostefano R, **Evans SR**. Benefit-Risk Assessments of Medical Treatments. *Pharmacoepidemiology Textbook*, Third Edition. Edited by Strom BL, Kimmel SE, and Hennessy S. 2020.
2. Levitan B, DiSantostefano R, **Evans SR**. Benefit-Risk Assessments of Medical Treatments. *Pharmacoepidemiology*, Sixth Edition. Edited by Strom BL, Kimmel SE, and Hennessy S. 2018.
3. **Evans SR**, Barry W. Interim Analysis and Data Monitoring. In: Kelly WK, Halabi S, editors. *Oncology Clinical Trials: Successful Design, Conduct, and Analysis*. 2<sup>nd</sup> edition. New York: Demos Medical Publishing; 2018. pp. 290-302.
4. Moyses RA, Angelim V, **Evans SR**. Non-inferiority Design. In: Fregni F, Illigens BMW, editors. *Critical Thinking in Clinical Research: Applied Theory and Practice Using Case Studies*. 1<sup>st</sup> ed. Oxford: Oxford University Press; 2017. Chapter 15.
5. Jiang Q, Ma H, Chuang-Stein C, **Evans SR**, He W, Quartey G, Scott J, Wen S, Arani R. Understanding and Evaluating Uncertainties in the Assessment of Benefit-Risk in Pharmaceutical Drug Development. In: Jiang Q, He W, editors. *Benefit-Risk Assessment Methods in Medical Product Development: Bridging Qualitative and Quantitative Assessments*. 1<sup>st</sup> ed. Boca Raton: Chapman & Hall/CRC Biostatistics Series; 2016. p. 71-84.
6. Wen S, He W, **Evans SR**, Ma H, Chuang-Stein C, Jiang Q, Li X, Quartey G, Arani R. Visualization of Benefit-Risk Assessment in Medical Products with Real Examples. In: Jiang Q, He W, editors. *Benefit-Risk Assessment Methods in Medical Product Development: Bridging Qualitative and Quantitative Assessments*. 1<sup>st</sup> ed. Boca Raton: Chapman & Hall/CRC Biostatistics Series; 2016. p. 197-231.
7. He W, Bloomfield D, Mai Y, **Evans SR**. Practical Considerations for Benefit Risk Assessment and Implementation: Vorapaxar TRA-2P TIMI 50 Case Study. In: Jiang Q, He W, editors. *Benefit-Risk Assessment Methods in Medical Product Development: Bridging Qualitative and Quantitative Assessments*. 1<sup>st</sup> ed. Boca Raton: Chapman & Hall/CRC Biostatistics Series; 2016. p. 235-249.
8. Asakura K, Hamasaki T, **Evans SR**, Sugimoto T, Sozu T. Group-sequential designs when considering two binary outcomes as co-primary endpoints. In: Chen Z, Aiyi L, Qu Y, Tang L, Ting N, Tsong Y, editors. *Applied Statistics in Biomedicine and Clinical Trial Designs*. 1<sup>st</sup> ed. Basel: Springer International Publishing; 2015. p. 235-265.

### Books

1. **Evans SR**, Ting N. *Fundamental Concepts for New Clinical Trialists*. 1<sup>st</sup> ed. Boca Raton: Chapman & Hall/CRC Biostatistics Series; 2016.
2. Sozu T, Sugimoto T, Hamasaki T, **Evans SR**. *Sample size determination in clinical trials with multiple endpoints*. 1<sup>st</sup> ed. New York: Springer; 2015.
3. Hamasaki T, Asakura K, **Evans SR**, Ochiai T. *Group-Sequential Clinical Trials with Multiple Co-Objectives*. 1<sup>st</sup> ed. New York: Springer; 2016.

### Letters: Research Letters

1. **Evans SR**. Response to Loewenthal et.al. <https://doi.org/10.1093/cid/ciac351> *Clinical Infectious Diseases*, ciac351, 2022.
2. **Evans SR**. Corrigendum to: Desirability of Outcome Ranking (DOOR) and Response Adjusted for Duration of Antibiotic Risk (RADAR), *CID*, 2022.
3. Proschan M, **Evans S**. Reply to Chandereng and Chappell. *Clinical Infectious Diseases* 2021;73(3):560.
4. Proschan M, **Evans S**. Reply to Villar et.al. *Clinical Infectious Diseases* 2021;73(3):560. Vol. 73, Issue 3, 1 August 2021, Pages e842–e843, <https://doi.org/10.1093/cid/ciaa1029>.



5. Wilson BM, Perez F, Pan Q, Jiang Y, **Evans SR**, Bonomo RA. Acinetobacter Infections. *Clinical Infectious Diseases*. Vol. 71, Issue 5, 1 September 2020, Pages 1357–1358, <https://doi.org/10.1093/cid/ciz1099>.
6. Wilson BM, Perez F, Pan Q, Jiang Y, **Evans SR**, Bonomo RA. Acinetobacter Infections. *Clin Inf Dis*. 71:5, pp. 1357–1358. doi.org/10.1093/cid/ciz1099, 2020.
7. Bonomo R, **Evans SR**. Response letter to comments. 2019. In: Rapid Molecular Diagnostics to Inform Empiric Use of Ceftazidime/Avibactam and Ceftolozane/Tazobactam Against *Pseudomonas aeruginosa*: PRIMERS IV. *Clin Inf Dis*.
8. **Evans, SR**, Kreiswirth B, Fowler V, Chambers H, Patel R, Hujer AM, Perez R, Bonomo RA. Reply to Lesho and Clifford: “In the eye of a storm”: the goal of rapid molecular diagnostics in PRIMERS I and II. *CID*. 2016.
9. **Evans SR**, Follmann D, Schoenfeld D, Chambers HF. Response to Phillips et.al. *CID*. 2015.
10. Fichtenbaum CJ, **Evans SR**, Aberg JA. Letter to *AIDS*. 2011. Letter Correspondence with International AIDS Society Journal re: High-Sensitivity C-Reactive Protein Levels do not Decrease with the Use of Statins in All Persons with HIV Infection. *AIDS*. 2011; 25 (16):2053.
11. Clifford DB, Smurzynski M, Zhao Y, Park LS, Blair L, Arens M, **Evans SR**. Response letter to comments. 2009. In: The Neurological Effects of Active Hepatitis C Virus Replication on Cognition in Treated HIV Patients. *Neurology*. 2009; 73:309-314.

#### **Letters: Editors Letter**

1. **Evans SR**. Editors Letter. *CHANCE* 32:4:2019.
2. **Evans SR**. Editors Letter. *CHANCE* 32:3:2019.
3. **Evans SR**. Editors Letter. *CHANCE* 32:2:2019.
4. **Evans SR**. Editors Letter. *CHANCE* 32:1:2019.
5. **Evans SR**. Editors Letter. *CHANCE* 31:4:2018.
6. **Evans SR**. Editors Letter. *CHANCE* 31:3:2018.
7. **Evans SR**. Editors Letter. *CHANCE* 31:2:2018.
8. **Evans SR**. Editors Letter. *CHANCE* 31:1:2018.
9. **Evans SR**. Editors Letter. *CHANCE* 30:4:2017.
10. **Evans SR**. Editors Letter. *CHANCE* 30:3:2017.
11. **Evans SR**. Editors Letter. *CHANCE* 30:2:2017.
12. **Evans SR**. Editors Letter. *CHANCE* 30:1:2017.
13. **Evans SR**. Editors Letter. *CHANCE* 29:4:2016.
14. **Evans SR**. Brief bits of humor in statistics: a statistician is ... *CHANCE* 29:4:61. 2016.
15. **Evans SR**. Editors Letter. *CHANCE* 29:3:2016.
16. **Evans SR**. Editors Letter. *CHANCE* 29:2:2016.
17. **Evans SR**. Editors Letter. *CHANCE* 29:1:2016.
18. **Evans SR**. Editors Letter. *CHANCE* 28:4:2015.
19. **Evans SR**. Editors Letter. *CHANCE* 28:3:2015.
20. **Evans SR**. Editors Letter. *CHANCE* 28:2:2015.
21. **Evans SR**. Editors Letter. *CHANCE* 28:1:2015.
22. **Evans SR**. Editors Letter. *CHANCE* 27:4:2014.
23. **Evans SR**. Editors Letter. *CHANCE* 27:3:2014.
24. **Evans SR**. Editors Letter. *CHANCE* 27:2:2014.
25. **Evans SR**. Editors Letter. *CHANCE* 27:1:2014.

#### **Letters: Newsletters**

1. Batt S, Fugh-berman AF, Dosi P, **Evans SR**, Kesselheim A, Lurie P, Molchan S, Powers J, Ramachandran R, Wood S. What needs to change at the FDA? <https://bit.ly/3BYHe5n>, PharmedOUT.org 2022.
2. **Evans SR**. CHANCE Highlights: Can a Statistical Concept Help Solve Political Gridlock? *AmSTAT News*, page 8. May, 2019.
3. **Evans SR**. CHANCE Highlights: Special issue looks at statistics in defense and national security. *AmSTAT News*, page 8. May, 2018.
4. **Evans SR**. CHANCE Highlights: Special issue focuses on climate change. *AmSTAT News*, January, 2018.
5. **Evans SR**. The 2017 New England Symposium on Statistics in Sports (NESSIS) Features Retrodictive Modeling, Shot Taxonomy, Randomness. *AmSTAT News*. December 2017.
6. **Evans SR**, The SCT Trial of the Year. *Society for Clinical Trials Newsletter*, 2017.
7. **Evans SR**, Glickman M. The 2017 New England Symposium on Statistics in Sports, *Newsletter of the Boston Chapter of the American Statistical Association*, 2017.
8. **Evans SR**, Glickman M. The 2015 New England Symposium on Statistics in Sports, *Newsletter of the Boston Chapter of the American Statistical Association*, 2015.
9. **Evans SR**. The New England Statistics Symposium Sets Record Attendance. *AmSTAT News*. December 2015.
10. Cook S, **Evans SR**, Goldman R, Li M, McKenzie J, Williams K. Attractions in Boston and Cambridge. *AmSTAT News*. Issue #443, pp. 26-27. May 2014.
11. **Evans SR**. The New England Statistics Symposium a Success. *Newsletter of the Boston Chapter of the American Statistical Association*. 2014.
12. **Evans SR**, Glickman M. New England Symposium on Statistics in Sports Bridges Gaps, *AmSTAT News*, page 15, January 2013.
13. **Evans SR**, Glickman M. The 2013 New England Symposium on Statistics in Sports, *Newsletter of the Boston Chapter of the American Statistical Association*, 2013.
14. **Evans SR**. Annual Fund Drive Reaches Still Higher. *AmSTAT News*, February, p. 10-15, 2012.
15. **Evans SR**, Glickman M. Statistics in Sports Symposium Draws Enthusiasm, *AmSTAT News*, page 15, January 2012.
16. O'Brien L, Horton N, **Evans SR**. An introduction to Mu Sigma Rho for American Statistical Association Chapters. *Chapter Chatter (ASA)* 2:2:10-12. 2012.
17. **Evans SR**. Annual Fund Drive Reaches New Heights. *AmSTAT News*, February, p. 6-11, 2011.
18. **Evans SR**, Glickman M. The 2011 New England Symposium on Statistics in Sports, *Newsletter of the Boston Chapter of the American Statistical Association*, 2011.
19. **Evans SR**. The ASA Annual Fund Drive. *AmSTAT News*, February, p. 6-11, 2010.
20. Hamasaki T, **Evans SR**, Molenburgh G. Biostatistics on the Rise in Japan. *AmSTAT News*, November, 2009.
21. Oster R, Lapidus J, **Evans SR**. New Award Winners and JSM 2008 Program. *AmSTAT News*, July, 2008.
22. **Evans SR**. Chair's Report, *Newsletter of the Teaching Statistics in the Health Sciences Section of the American Statistical Association*, spring, 2008.
23. **Evans SR**. Chair's Report, *Newsletter of the Teaching Statistics in the Health Sciences Section of the American Statistical Association*, summer, 2008.
24. **Evans SR**. Chair's Report, *Newsletter of the Teaching Statistics in the Health Sciences Section of the American Statistical Association*, fall, 2008.
25. **Evans SR**. President's Report, *Newsletter of the Boston Chapter of the American Statistical Association*, 2006.

26. **Evans SR.** Changing Endpoints after a Clinical Trial Begins, *TMT Medical News*, [http://masterdocs.com/PDF/Changing\\_Endpoints\\_After\\_A\\_Clinical\\_Trial\\_Begins\\_By\\_Scott\\_Evans.pdf](http://masterdocs.com/PDF/Changing_Endpoints_After_A_Clinical_Trial_Begins_By_Scott_Evans.pdf), 2006.
27. **Evans SR.** Distance Education and Teaching Statistics in the Health Sciences. *Newsletter of the Teaching Statistics in the Health Sciences Section of the American Statistical Association*, fall, 2005.
28. **Evans SR.** President's Report, *Newsletter of the Boston Chapter of the American Statistical Association*, 2005.
29. Horton N, **Evans SR.** An Introduction to Mu Sigma Rho (or a Simple Guide to Honoring Outstanding Students of Statistics in Your Midst). *AmStat News*, Issue number 341, page 50, November, 2005.
30. Bernson M, **Evans SR.** Tutorials in Medicine: An Introduction to Clinical Trials; Part I of II: Purposes and Phases. <http://www.nextgenmd.org/vol1-4/clinicaltrialsv1i4.html>, *The Next Generation*, 2005.
31. Bernson M, **Evans SR.** Tutorials in Medicine: An Introduction to Clinical Trials; Part II of II: Statistics and Experimental Design. <http://www.nextgenmd.org/vol1-5/clinicaltrialsv1i5.html>, *The Next Generation*, 2005.
32. **Evans SR.** President's Report, *Newsletter of the Boston Chapter of the American Statistical Association*, 2004.
33. **Evans SR.** President's Report, *Newsletter of the Boston Chapter of the American Statistical Association*, 2003.
34. **Evans SR,** Kleinman K, Pagano M. Statistics in Defense and National Security: Bioterrorism and Biosurveillance. *AMSTAT News*, pp. 41-43, July, 2002.

#### **Published Interviews and Press Releases: Interviewee**

1. Interview with Scott Evans, Key Opinion Leader. BenefitRisk Assessment Planning (BRAP).
2. Interview with Scott Evans, Key Opinion Leader. Biometrics in Pharma.
3. The Art of Storytelling: How to Communicate Clinical Data More Effectively. Biopharmaceutical Section of the ASA. Podcast, 2021. <https://fyyd.de/episode/6628038>
4. Healthy You Podcast. Milken Institute School of Public Health, George Washington University. 2020.
5. Stats & Stories. Superbugs and Statistics. 2019. <https://statsandstories.net/health1/superbug-statistics>
6. Stats & Stories. Sports and Statistics. 2019. <https://soundcloud.com/statsandstories/sports-stats-in-2019/s-FidnI>
7. Internationally Recognized Leader in Clinical Trials, Biostatistics, and Infectious Disease Research Joins the George Washington University. <https://publichealth.gwu.edu/content/internationally-recognized-leader-clinical-trials-biostatistics-and-infectious-disease>. 2018.
8. Cytel and Scott Evans. How can Novel Statistical Methods Tackle Antibiotic Resistance? Interview with Scott Evans. Cytel Blog. <http://www.cytel.com/blog/novel-statistics-antibiotic-resistance-scott-evans>. 2017.
9. Evans SR. Q&A with Scott Evans, CHANCE Executive Editor. American Statistical Association. <http://www.amstat.org/ASA/Publications/Q-and-As/Scott-Evans.aspx>.
10. Outsmarting Superbugs. Plymouth Magazine. <https://www.plymouth.edu/magazine/alumni-green/outsmarting-superbugs/>. 2016.
11. Superbugs: An Epidemic Begins. Harvard Magazine. <http://harvardmagazine.com/2014/05/superbug>. 2014.

#### **Published Interviews: Interviewer**

1. DeMets D, Pocock S, Evans SR. A Conversation with Dave DeMets and Stuart Pocock. Washington DC. December, 2022.
2. Wei LJ, Evans SR. A Conversation with LJ Wei. ICSA Newsletter. 2017.
3. Molenberghs G, Hamasaki T, Evans SR. An Interview with Geert Molenberghs. CHANCE 30:1:16-23, 2017.
4. Mehta C, Patel N, Evans SR. Creators of Pioneering Software Development Company Look Back and to the Future. CHANCE 29:3:51-57, 2016.
5. Evans SR, Kovalchik S, Lock D. Want a Career in Sports Analytics? Webinar. American Statistical Association, 2016.
6. O'Neill R. and Evans, SR. A Conversation with Bob O'Neill. Podcast available at: <http://community.amstat.org/biop/podcast>. Boston Chapter of the ASA, 2014. <https://fyyd.de/episode/287338>
7. Wittes J. and Evans SR. An Interview with Janet Wittes, President of Statistics Collaborative. CHANCE 27:4:15-22, 2014.

### **Published Statements**

1. Statement of the Council for International Organizations of Medical Sciences (CIOMS) International Expert Working Group. Medicines assessment during public health emergencies needs good science, best practices and proper communication. [https://cioms.ch/wp-content/uploads/2020/06/CIOMS\\_WGXII\\_Statement.pdf](https://cioms.ch/wp-content/uploads/2020/06/CIOMS_WGXII_Statement.pdf). June 3, 2020.
2. ASA Board of Directors releases 2020 Census Quality Indicators and endorses its recommendations, <https://www.amstat.org/asa/files/pdfs/POL-2020CensusQualityIndicators.pdf> 10/13/20.
3. ASA Board issues Statement on Creation and Appointment of US Census Bureau Deputy Director of Data, <https://www.amstat.org/asa/files/pdfs/POL-CensusDataDepDirectorStatement.pdf> 9/1/2020.
4. ASA Board issues Statement on Ensuring Fair and Accurate 2020 Census, <https://www.amstat.org/asa/files/pdfs/POL-DecennialCensusTimeline.pdf> 7/31/20.
5. ASA Board issues Statement on the July 21 Executive Order Regarding the Decennial Census, <https://www.amstat.org/asa/files/pdfs/POL-DecennialCensusEO.pdf> 7/21/20.
6. ASA Board issues Statement on New HHS COVID-19 Guidance for Hospital Reporting, <https://www.amstat.org/asa/files/pdfs/POL-July10Covid19HospitalReportingGuidelines.pdf> 7/16/20.
7. ASA Board issues Statement and Request on the June 23 Census Bureau Appointments, <https://www.amstat.org/asa/files/pdfs/POL-June23CensusBureauAppointments.pdf> 6/24/20.
8. ASA Board issues Statement on the Role of Data Experts within the Government, Especially during a Public Health Emergency, <https://www.amstat.org/asa/files/pdfs/POL-RoleOfDataExpertsWithinGovernment.pdf> 5/26/20.
9. ASA Issues New Statement of Support for Greek Statistician Andreas Georgiou, <https://www.amstat.org/asa/files/pdfs/pressreleases/2019-ASA-supports-Andreas-Georgiou.pdf>. press release, 12/10/19.
10. ASA endorses Principles and Best Practices for Post-Election Tabulation Audits, <https://www.amstat.org/asa/News/ASA-Endorses-Post-Election-Audits-Principles.aspx> announcement, 1/9/19.
11. ASA Position on Statistical Statements for Forensic Evidence, <https://www.amstat.org/asa/files/pdfs/POL-ForensicScience.pdf> 1/2/19.
12. ASA Board of Directors Statement of Concern for the USDA Economic Research Service and on the Vital and Unique Role of Federal Statistical Agencies, [https://www.amstat.org/asa/files/pdfs/POL-ERS\\_FederalStatistics.pdf](https://www.amstat.org/asa/files/pdfs/POL-ERS_FederalStatistics.pdf) 12/3/18.

13. ASA Board Decries Second Annulment of Former Greece Chief Statistician's Acquittal, <https://www.amstat.org/ASA/News/ASA-Board-Decries-Second-Annulment-of-Former-Greece-Chief-Statisticians-Acquittal.aspx> 5/17/18.
14. ASA approves Ethical Guidelines for Statistical Practice, <https://www.amstat.org/ASA/Your-Career/Ethical-Guidelines-for-Statistical-Practice.aspx> April 2018.
15. ASA Board issues Statement Regarding Decision to Add Citizenship Question to Decennial Census, <https://www.amstat.org/asa/files/pdfs/POL-CitizenshipQuestion.pdf> 3/29/18.
16. The ASA & the American Mathematical Society issue joint statement regarding drawing of voting districts and partisan gerrymandering, <https://www.amstat.org/asa/files/pdfs/POL-GerrymanderingStatement2018.pdf> 1/24/18.
17. ASA Board endorses a position paper, "Statistics as a Scientific Discipline and Practical Implications for the Evaluation of Faculty Excellence," <https://www.amstat.org/asa/files/pdfs/POL-Statistics-as-a-Scientific-Discipline.pdf> 1/5/18.

### Abstracts (Last Three Years)

1. Chamberlain J, Silbergleit R, Elm J, Rosenthal ES, Bleck T, Shinnar S, Zehtabchi S, **Evans SR**. DOOR-STEP: A Desirability of Outcome Ranking Scale for Clinical Trials of Status Epilepticus Treatment. Pediatric Academic Societies (PAS) Annual Meeting, 2022.
2. Kinamon T, Gopinath R, Waack U, Needles M, Rubin D, Collyar D, Doernberg S, **Evans SR**, Hamasaki T, Holland T, Howard-Anderson J, Chambers H, Fowler, Jr., VG, Nambiar S, Kim P, Boucher HW. Development and Analysis of a Novel DOOR Endpoint for Complicated Intra-abdominal Infections (cIAI) Using 10 Registrational Trials for Antibacterial Drugs. IDWEEK, 2022.
3. Sandoval et.al., Desirability Of Outcome Ranking (DOOR) Methodology Applied to a Trial of Induction versus Expectant Management. Society for Maternal Fetal Medicine. 2023.
4. Chamberlain J, Silbergleit R, Elm J, Rosenthal ES, Bleck T, Shinnar S, Zehtabchi S, **Evans SR**. DOOR-STEP: A Desirability of Outcome Ranking Scale for Clinical Trials of Status Epilepticus Treatment. American Epilepsy Society (AES) Annual Meeting, 2021.
5. Amarenco P, Denison H, **Evans SR**, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Wang Y, Johnston SC. Ticagrelor Added to Aspirin in Acute Nonsevere Ischemic Stroke or Transient Ischemic Attack of Atherosclerotic Origin. American Heart Association. 2021.
6. Molina C, Amarenco P, Ladenvall P, Aunes M, Denison H, **Evans S**, Himmelmann A, Jahreskog M, James S, Knutsson M, Nylander S, Röther J, Wang Y, Johnston SC. Ticagrelor Plus Aspirin Versus Aspirin Alone in Acute Ischemic Stroke or TIA – Analysis of Bleeding Events in the THALES Trial. American Heart Association. 2021.
7. Howard-Anderson JR, Earley M, Hamasaki T, Bower CW, Smith G, van Duin D, **Evans SR**, Jacob JT. Unfavorable Clinical Outcomes with Polymyxins Compared to Ceftolozane/Tazobactam for the Treatment of Carbapenem-Resistant *Pseudomonas aeruginosa* Infections. IDWEEK, 2021.
8. Howard-Anderson JR, Bower CW, Smith G, **Evans S**, van Duin D, Jacob JT. Increased Mortality with Polymyxins Compared to Ceftolozane/Tazobactam in Carbapenem-Resistant *Pseudomonas aeruginosa*. UT Center for Antimicrobial Resistance and Microbial Genomics (CARMIG), 2021.
9. Shropshire WC, Dinh AQ, Komarow L, Earley M, Panesso D, Rydell K, Gómez-Villegas SI, Miao H, Hill C, Chen L, Patel R, Fries BC, Dhar S, Jacob JT, Salata R, Cober E, Kalayjian R, Garcia-Diaz J, Weston G, Abbo L, **Evans S**, Chambers H, Fowler V,

- Shelburne SA, Kreiswirth BN, Bonomo RA, van Duin D, Hanson BM, Arias CA. Parallel, endemic dissemination of carbapenem resistant CG307 and CG258 *Klebsiella pneumoniae* lineages with unique accessory genomes in Houston, TX. UT Center for Antimicrobial Resistance and Microbial Genomics (CARMIG), 2021.
10. Johnston SC, Amarenco P, Aunes M, Denison H, **Evans SR**, Himmelmann A, Jahreskog M, James S, Knutsson M, Ladenvall P, Molina CA, Nylander S, Röther J, Wang Y. Ischemic Benefit and Hemorrhagic Risk of Ticagrelor-Aspirin vs. Aspirin in Patients with Acute Ischemic Stroke or TIA. ESOC, 2021.
  11. Wang Y, Pan Y, Li H, Amarenco P, Denison H, **Evans SR**, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina CA, Johnston SC. Time course for benefit and risk of ticagrelor and aspirin after acute ischemic stroke and transient ischemic attack: a secondary analysis from the THALES trial. World Stroke Congress (WSO), 2021.
  12. Wang Y, Pan Y, Li H, Amarenco P, Denison H, **Evans SR**, Himmelmann A, James S, Birve F, Ladenvall P, Molina CA, Johnston SC. Efficacy and safety of ticagrelor and aspirin in moderate ischemic stroke in the THALES trial. Tiantan International Stroke Conferences (TISC), 2021.
  13. McEwan P, Darlington O, Knutsson M, Denison H, Ladenvall P, Amarenco P, Johnston SC, **Evans SR**, James S, Himmelmann A, Venditto J, Mellstrom C, Atreja N, Tank A. Estimating the Reduction in Medical Care Costs Associated with Ticagrelor and Aspirin in Patients with Acute Ischemic Stroke or TIA. ISPOR - The Professional Society for Health Economics and Outcomes Research, 2021.
  14. Tank A, Johnston SC, Jain R, Amarenco P, Mellstrom C, Rikner K, Denison H, Ladenvall P, Knutsson M, Himmelmann A, **Evans SR**, James S, Monina CA, Wang Y, Ouwens M. Cost Effectiveness of Ticagrelor plus Aspirin vs. Aspirin Alone in Acute Stroke or Transient Ischemic Attack: an Economic Evaluation of the THALES Trial. ESOC, 2021.
  15. Johnston SC, Amarenco P, Denison H, **Evans SR**, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina C, Wang Y. Ticagrelor and aspirin versus aspirin alone in acute ischemic stroke and TI: Results of the THALES trial. ESOC, Vienna, Austria. 2020.
  16. Uschner D, Hamasaki T, Pan Q, Dai W, Early M, **Evans SR**. Patient-centric outcomes in clinical trials: The Desirability of Outcome Ranking. International Society for Clinical Biostatistics. 2020.
  17. Williams DJ, Creech CB, Walter EB, Martin J, Gerber J, Newland J, Howard L, Kimberlin D, Staat M, Pettigrew M, Fowler Jr VG, Chambers HF, Zaoutis T; **Evans SR**, Huskins WC. Randomized Double-Blind Controlled Trial of Short vs. Standard Course Outpatient Therapy of Community Acquired Pneumonia in Children (SCOUT-CAP). IDWEEK, 2020.
  18. Yin X, Hamasaki T, **Evans SR**. Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS): Design Considerations for Selecting the Optimal Treatment. Society for Clinical Trials. 2020.
  19. Yin X, Hamasaki T, **Evans SR**. Sequential, Multiple-Assignment, Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS): Design Considerations for Selecting the Optimal Treatment. Biopharmaceutical Section Regulatory Industry Statistics Workshop. 2020.
  20. Hamasaki T, Hsiao CF, Evans SR. Selecting Critical Boundaries in Group-sequential Trials with Multiple Endpoints. JSM, Denver, CO. 2019.
  21. Doernberg SB, Komarow L, Tran TTT, Sund Z, Pandori MW, Jensen D, Tsalik EL, Deal CD, Chambers HF, Fowler Jr VG, **Evans SR**, Patel R, Klausner JD. A Master Protocol for Simultaneous Evaluation of Multiple Diagnostic Assays to Detect *Neisseria gonorrhoeae* and *Chlamydia trachomatis* in Extragenital Sites: MASTER GC. ASM Microbe. San Francisco, CA. 2019.

22. Van Duin D, Arias C, Weston G, et.al., National variability in patients with carbapenem-resistant Enterobacteriaceae in the US; First results from the Consortium on resistance against carbapenems in Klebsiella and other Enterobacteriaceae-II. ASM Microbe. San Francisco, CA. 2019.
23. Domitrovic Tn, Hujer AM, Rojas LJ, et.al., *Serratia marcescens* producing KPC: an emerging Pahtogen in the United States? ASM Microbe. San Francisco, CA. 2019.
24. Claeys KC, Hopkins TL, Rogers Z, **Evans SR**, Jiang Y, Johnson JK, Leekha S. Comparison of Rapid Diagnostic Tests for Bloodstream Infections using Desirability of Outcome Ranking Management of Antimicrobial Therapy (DOOR-MAT). IDWEEK. Washington DC, 2019.
25. Claeys KC, Schlaffer K, Rogers Z, **Evans SR**, Jiang Y, Johnson JK, Leekha S. Comparing the Clinical Utility of Rapid Diagnostic Tests for Gram-negative Bloodstream Infection using a Desirability of Outcomes Ranking. IDWEEK. Washington DC, 2019.
26. Johnston SC, Mellstrom C, Ouwens M, **Evans SR**, Denison H, Ladenvall P, Parkhomenko E, Knutsson M, Rikner K, Wang Y, Smare C, Amarenco P. Health-related Quality of Life within 90 Days after Acute Ischemic Stroke or Transient Ischemic attack: Data from the SOCRATES Trial. ESOC. Milan, Italy, 2019.
27. Johnston SC, Mellstrom C, Ouwens M, **Evans SR**, Denison H, Ladenvall P, Parkhomenko E, Knutsson M, Rikner K, Wang Y, Smare C, Amarenco P. Healthcare resource utilization after subsequent stroke in patients with acute ischemic stroke or transient ischemic attack: data from the SOCRATES trial ESOC. Milan, Italy, 2019.
28. Wilson B, Viau R, Perez F, Jiang Y, Fowler VG Jr, Chambers HF, Bonomo BA, **Evans SR**. Using the Desirability of Outcome Ranking for Management of Antimicrobial Therapy (DOOR-MAT) to assess antibiotic therapy guided by rapid molecular diagnostics (RMD) in bloodstream infections (BSI) caused by *Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kpn*). IDWEEK. 2018.
29. Hamasaki T, **Evans SR**, Sugimoto T, Asakura K. Statistical Monitoring of Semi-competing Risk Outcomes in Clinical Trials. JSM. 2018.
30. Hamasaki T, **Evans SR**, Halabi S, Sugimoto T, Asakura K. Group Sequential Strategies in Clinical Trials with Bivariate Time-to-Event Outcomes. ENAR. 2018.
31. Hamasaki T, Asakura K, **Evans SR**, Halabi S, Sugimoto T. Designing Efficient Clinical Trials with Multiple Time-to-event Outcomes. IMS-APRM. Singapore. 2018.
32. Hamasaki T, **Evans SR**, Halabi S, Sugimoto T, Asakura K. Group Sequential Logrank-Based Methods for Monitoring Bivariate Non-Competing Event-Time Outcomes in Clinical Trials. DIA/FDA Statistics Forum. 2018.
33. Hamasaki T, **Evans SR**, Sugimoto T, Asakura K. Designing Complex Survival Clinical Trials with Multi-stage and Multiple Endpoints. International Biometric Conference. 2018.
34. Asakura K, Hamasaki T, **Evans SR**. Interim monitoring for futility of clinical trials with co-primary endpoints. ASA Biopharmaceutical Section Statistics Workshop. 2018.
35. Viau R, Wilson B, **Evans SR**, Perez F, Fowler Jr. VG, Chambers HF, Kreiswirth BN, Banerjee R, Patel R, Bonomo RA. Do healthcare providers de-escalate Beta-lactam (BL) antibiotic therapy based on results of antibiotic susceptibility testing (AST)? Analysis of bloodstream infections (BSI) caused by *Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kpn*) from the Veterans Health Administration (VHA). IDWEEK. 2018.
36. Viau R, Wilson B, **Evans SR**, Perez F, Fowler Jr. VG, Chambers HF, Kreiswirth BN, Bonomo RA. How do healthcare providers approach empiric beta-lactam (BL) treatment of bloodstream infections (BSI) caused by Gram negative rods (GNRs)? Analysis of *Escherichia coli* (*Ec*) and *Klebsiella pneumoniae* (*Kpn*) BSI from the Veterans Health Administration (VHA). IDWEEK. 2018.

37. Hujer A, Long W, Olsen R, Kreiswirth BN, **Evans SR**, Musser J, Bonomo RA. Predicting B-Lactam Resistance Using Whole Genome Sequencing (WGS) in *Klebsiella pneumoniae*: the Challenge of B-Lactam Inhibitors. IDWEEK. 2018.
38. Henderson H, Lueterbach CL, Cober E, Richter SS, Salata RA, Kalayjian RC, Watkins RR, Doi Y, Kaye KS, **Evans SR**, Fowler Jr VG, Bonomo RA, Harris A, Napravnik S, van Duin D. Optimizing Prediction of Mortality in Patients Infected with Carbapenem-resistant Enterobacteriaceae. IDWEEK. 2018.
39. Johnston SC, Amarenco P, Denison H, **Evans SR**, Himmelmann A, James S, Knutsson M, Ladenvall P, Molina C, Wang Y. The THALES (Acute STroke or Transient Ischaemic Attack Treated with TicAgreLor and ASA for PrEvention of Stroke and Death) Trial Design. European Stroke Organization Conference. Gothenburg, Sweden. 2018.
40. Hamasaki T, Asakura K, **Evans SR**, Sugimoto T, Yamamoto H. Interim Evaluation of Futility Group-sequential Trials with Two Time-to-event Outcomes. Society for Clinical Trials. 2018.
41. **Evans SR**, Curtis L, Perlmutter J, Sheehan J, Tomaino J, Hamre G. Understanding the Clinical Trial Enterprise's Newest Trend: Incorporating Real-World Evidence into Randomized Clinical Trials. Society for Clinical Trials. 2018.
42. Easton JD, Denison H, Knutsson M, Amarenco P, Albers GW, **Evans SR**, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL, Johnston SC. Estimated Treatment Effect of Ticagrelor vs. Aspirin by Investigator Assessed Events Compared with Judgement by an Independent Event Adjudication Committee in the SOCRATES Trial. European Stroke Organization Conference. Gothenburg, Sweden. 2018.
43. Doernberg S, Holland T, Paul M, Yahav D, Tran T, **Evans SR**, Cosgrove S, Boucher HW, Corey GR, Fowler VG, Chambers H, Leibovici L. Desirability of Outcome Ranking (DOOR) analysis of patients with methicillin-resistant *Staphylococcus aureus* bloodstream infections (BSIs) from a trial comparing trimethoprim-sulfamethoxazole (TMP-SMX) versus vancomycin. European Congress of Clinical Microbiology and Infectious Diseases (ECCMID). 2018.

### **Scholarly Presentations**

#### **Regional Presentations**

1. **Evans SR**. Hosmer DW. Goodness of Fit in Two Models for Clustered Binary Data. Probability and Statistics Seminar, University of Massachusetts, Amherst, MA, 1998.
2. **Evans SR**. Hosmer DW. Goodness of Fit in Two Models for Clustered Binary Data. Department of Biostatistics and Epidemiology Doctoral Student Seminar, University of Massachusetts, Amherst, MA, 1998.
3. **Evans SR**. Equivalence Trials. Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 2001.
4. **Evans SR**. Biostatistics in Medical and Public Health Research. Information Technology in Healthcare Working Group, Harvard Medical School, Boston, MA, 2003.
5. **Evans SR**. Statistical Careers in Clinical Trials, Bioterrorism, and Ecology. Statistics Career Night, BCASA, Boston, MA, 2003.
6. Zhang J, **Evans SR**. Informative Censoring: Practical Considerations. HIV Working Group, HSPH, Boston, MA, 2004.
7. **Evans SR**. Designs in Clinical Trials. Introduction to Statistics, Harvard Extension School, Cambridge, MA, 2004.
8. **Evans SR**. Biostatistics for High School Teachers. New Hampshire IMPACT Center, Plymouth State University, 2004.
9. **Evans SR**. What Do Biostatisticians Do? Mathematics Association at Plymouth State University, Co-Sponsored by the BCASA, Plymouth, NH, 2004.



10. Li L, **Evans SR**. A Comparison of Goodness-of-Fit Tests for the Logistic GEE Model. Longitudinal Data Working Group, HSPH, Boston, MA, 2004.
11. Yang Y, **Evans SR**. Recent Results in Neuro-AIDS Clinical Trials. Neuro-Statistics Working Group, HSPH, Boston, MA, 2004.
12. **Evans SR**. Exploring Mathematics Night: A Panel. Department of Mathematics and Statistics, University of New Hampshire, 2005.
13. **Evans SR**. Clinical Trials and Bioterrorism: Statistical Careers. Career Day, BCASA, Boston, MA, 2005.
14. **Evans SR**. Distance Education in Biostatistics: A Case Study. BCASA, Waltham, MA, 2006.
15. **Evans SR**. Why is Statistics Important? High School Statistics Day, BCASA, Newton, MA, 2006.
16. **Evans SR**. Futility Analyses and Predicted Intervals. CBAR, HSPH, Boston, MA, 2006.
17. **Evans SR**. Measuring LDL and Agreement. CBAR, HSPH, Boston, MA, 2006**Evans SR**. Statistics and Biostatistics as a Career. Mathematics Career Day, Bentley College, Waltham, MA, 2007.
18. **Evans SR**. Data Monitoring in Clinical Trials Using Prediction. Children's Hospital, Boston, Harvard Medical School, MA, 2007.
19. **Evans SR**. Careers in Biostatistics and Biostatistical Design. Mathematics Seminar, Emmanuel College, 2007.
20. Yeh TM, **Evans SR**. A5252: A Phase II Randomized, Double-Blind, Placebo-Controlled Study of Combination Analgesic Therapy in HIV-Associated Painful Peripheral Neuropathy. Design Review, CBAR, Boston, MA, 2007.
21. Chen H, **Evans SR**. Assessment of HIV-Related Oral Mucosal Disease and Use of Saliva in Measuring HIV Viral Load. Design Review, CBAR, Boston, MA, 2007.
22. **Evans SR, Ting N**. Careers in Clinical Trials and Biostatistics. Mathematics Career Day, University of Connecticut, 2008.
23. **Evans SR, Li L, Wei LJ**. Monitoring Clinical Trials Using Prediction. HIV Working Group, Department of Biostatistics, HSPH, Boston, MA, 2008.
24. **Evans SR**. Educating Young Students about Statistics and Study Design. Annual Meeting of the New Hampshire Teachers of Mathematics, 2008.
25. **Evans SR, Chen H, Yeh TM**. Neuropathy in the ALLRT Cohort. CBAR, HSPH, 2008.
26. **Evans SR**. Issues with Composite Endpoints. CBAR, HSPH, 2008.
27. Jiang H, **Evans SR**. A Randomized Clinical Trial of Chemotherapies for Kaposi's sarcoma in HIV. Design Review, CBAR, Boston, MA, 2008.
28. Chen H, **Evans SR**. A Randomized Clinical Trial of Gentian Violet vs. Nystatin for the Treatment of Oral Candidiasis in HIV. Design Review, CBAR, Boston, MA, 2008.
29. **Evans SR**. Benefit:Risk in Clinical Trials. Midwest Biopharmaceutical Statistics Workshop (MBSW), 2009.
30. **Evans SR**. Noninferiority Clinical Trials. Massachusetts General Hospital Biostatistics Center Seminar, 2009.
31. **Evans SR**. Noninferiority Clinical Trials. CBAR, HSPH, 2009.
32. **Evans SR and Wei LJ**. Data Monitoring: Life beyond p-values. CBAR Staff Meeting, 2009.
33. **Evans SR**. Data Monitoring of Clinical Trials Using Prediction. Harvard Catalyst Biostatistics Program Seminar, The Harvard Clinical and Translational Science Center, 2010.
34. **Evans SR**. Biostatistics in Clinical Trials. Association of Teachers of Mathematics in New England (ATMNE), 2010.
35. **Evans SR**. Statistical Consulting in Lawsuits: Panel Discussion. BCASA, Boston, MA, 2010.

36. **Evans SR.** Adaptive Design. CBAR, HSPH, 2010.
37. **Evans SR** and Wei LJ. Noninferiority and ITT. CBAR Staff Meeting, 2010.
38. **Evans SR.** Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2011.
39. **Evans SR.** Adapting Traditional Adaptive Designs: New Methods and Procedures. New Jersey Chapter of ASA, Annual Symposium on Adaptive Design, 2011.
40. **Evans SR.** Future HIV Clinical Trials: New Challenges. HIV Working Group, Department of Biostatistics, HSPH, 2011.
41. **Evans SR.** Academic Careers in Statistics. New England Statistics Symposium (NESS), 2011.
42. **Evans SR.** The Non-technical Side of Statistics: the Role of the Clinical Trial Statistician, CBAR, HSPH, 2011.
43. **Evans SR.** Benefit:risk Evaluation in Clinical Trials. CBAR, HSPH, 2011.
44. **Evans SR.** Noninferiority Clinical Trials. CBAR, HSPH, 2011.
45. **Evans SR.** Fundamentals of Clinical Trial Design. CBAR, HSPH, 2011.
46. Chen H, **Evans SR.** HPV and Oral Candidiasis. CBAR, HSPH, 2011.
47. Lee A, **Evans SR.** A Randomized Trial Comparing a LPV/r-Based to an nNRTI-Based Antiretroviral Therapy Regimen for Clearance of Subclinical *Plasmodium falciparum* Parasitemia in HIV-infected Individuals. Design Review, CBAR, Boston, MA, 2011.
48. **Evans SR.** Diagnostic Trials: Design, Analyses, and Reporting. CBAR, HSPH, 2013.
49. **Evans SR.** Prediction for Interim Data Monitoring of Clinical Trials. HIV Working Group, Department of Biostatistics, HSPH, 2012.
50. **Evans SR.** Predicting the Future to Aid in Decision-Making in Medical Studies. Career Day, BCASA, Boston, MA, 2012.
51. **Evans SR.** Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2012.
52. **Evans SR.** Exploring Mathematics Night: A Panel. Department of Mathematics and Statistics, University of New Hampshire, 2012.
53. **Evans SR.** What's the Question? CBAR, HSPH, 2012.
54. **Evans SR.** Benefit:risk Evaluation in Clinical Trials. CBAR, HSPH. 2012.
55. Lee A, **Evans SR.** Development of a Neuroimaging Network for the ACTG: Site Screening and Preparation a Limited Center Trial of the ACTG. Design Review, CBAR, Boston, MA, 2012.
56. **Evans SR.** Benefit:risk Evaluation in Clinical Trials. Tufts Clinical and Translational Science Institute, Tufts Medical Center, 2013.
57. **Evans SR.** Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2013.
58. **Evans SR.** Response Adjusted for Duration of Antibiotic Risk (RADAR). University of Rochester. Department of Biostatistics and Bioinformatics Seminar. 2014.
59. **Evans SR.** DSMBs. City of Hope. CA. 2014.
60. **Evans SR.** Antibacterial Resistance and the ARLG. CBAR, HSPH, 2014.
61. **Evans SR.** Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2014.
62. **Evans SR.** Clinical Trials, Pharmacogenomic Interplay in Biotransformation and Pharmacokinetics, University of Rhode Island. 2014.
63. **Evans SR.** Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2015.
64. **Evans SR.** Using endpoint data to analyze patients rather than patient data to analyze the endpoints. University of Vermont. 2015.
65. **Evans SR.** Using endpoint data to analyze patients rather than patient data to analyze the endpoints. University of Massachusetts. 2015.

66. **Evans SR.** Clinical Trials and Diagnostics: Biostatistical Ideas. Rutgers University. 2015.
67. **Evans SR.** Careers in Clinical Trials. Boston University Career Night. 2015.
68. **Evans SR.** DOOR and RADAR. CBAR, HSPH, 2015.
69. **Evans SR.** Superbugs vs. Statistics. Massachusetts General Hospital Biostatistics Center Seminar, 2016.
70. **Evans SR.** Clinical Trials: Today and Tomorrow. CBAR, HSPH. 2016.
71. **Evans SR.** Using endpoint data to analyze patients rather than patient data to analyze the endpoints. Harvard Pilgrim Health Care. 2016.
72. **Evans SR.** Noninferiority Clinical Trials. Principles and Practice of Clinical Research, Harvard Medical School, 2016.
73. **Evans SR.** Using endpoints to analyze patients rather than patients to analyze the endpoints. CBAR, HSPH. 2016.
74. **Evans SR.** Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: Healthy Disruption for Clinical Trials and Diagnostic Studies. Beth Israel Deaconess Medical Center. 2017.
75. **Evans SR.** Fighting Superbugs with Pragmatism: Healthy Disruption for Clinical Trials and Diagnostic Studies. Department of Statistics. George Washington University. 2018.
76. **Evans SR.** The Desirability of Outcome Ranking. Invited seminar, Vanderbilt University. 2020.
77. **Evans SR.** Our most important discovery: the question. Biostatistics Center. Milken Institute School of Public Health, 2021.
78. **Evans SR.** The Catalyst to Better Answers: More Thoughtful Questions. Biostatistics Center. Milken Institute School of Public Health, 2021.

### **National Presentations**

1. Ellis R, Robertson K, Yiannoutsos C, **Evans SR**, Bosch R. Association of HAART-Induced Virologic Suppression with the Prevalence and Incidence of HIV Neurocognitive Impairment and DSPN in the ALLRT Cohort. ACTG Meetings, Crystal City, VA, 2002.
2. Aberg J, Zackin R, **Evans SR**, Yang Y, Alston BL, Henry K, Glesby M, Brobst SW, Owens S, Fichtenbaum CJ. ACTG A5087: Comparing the Efficacy and Safety of Fenofibrate versus Pravastatin in HIV-Infected Subjects with Lipid Abnormalities. ACTG Meetings, Crystal City, VA, 2002.
3. Clifford DB, **Evans SR**, Yang Y, Acosta E, Gulick, RM. Impact of Efavirenz (EFV) on Neuropsychological Performance, Mood, and Sleep Behavior in HIV-Positive Individuals. ACTG Meetings, Washington, DC, 2003.
4. Robertson K, Ellis R, **Evans SR**, Yang Y. Clinical Validation of the ACTG Neuroscreen. ACTG Meetings, Washington, DC, 2003.
5. D'Amico R, **Evans SR**, Yang Y, Schnizlein-Bick C, Mildvan D. Pathogen-Specific Immune Responses in Opportunistic Infections. ACTG Meetings, Washington, DC, 2003.
6. **Evans SR.** Transition to Electronic or Web-based Newsletters. Council of Chapter Presentation, JSM, San Francisco, CA, 2003.
7. **Evans SR.** Assessment of the Agreement between the LDL Genzyme Assay and LDL Measured by Ultracentrifugation and the Applicability of the Friedewald Equation for Calculating LDL Measurements in ACTG A5087. ACTG Meeting, Baltimore, MD, 2005.
8. **Evans SR.** Phase II Trial of Prosaposin-derived Peptides for HIV-associated Sensory Neuropathies: First Use of Electronic Diary to Record HIV-Associated Neuropathic Pain. ACTG Meeting, Baltimore, MD, 2005.
9. **Evans SR.** The Value of Quantitative Measures in the Research Diagnosis of HIV-associated Neuropathy. ACTG Meeting, Baltimore, MD, 2005.
10. **Evans SR,** Mu Sigma Rho and ASA Chapters. Council of Chapters, JSM, Minneapolis, MN, 2005.

11. **Evans SR**, O'Neill R. Benefit:Risk Evaluation in Clinical Trials. Statistics Virtual Journal Club, Statistics Special Interest Area Community, Drug Information Association, 2008.
12. **Evans SR**, Li L, Wei LJ. Data Monitoring of Clinical Trials Using Prediction. ICSA, NJ, 2008.
13. **Evans SR**. Noninferiority Trials. ACTG Meetings, Washington DC, 2008.
14. **Evans SR**. Neuropathy in the ALLRT Cohort. ACTG Meetings, Washington DC, 2008.
15. **Evans SR**, Wei LJ. Data Monitoring of Clinical Trials Using Prediction. Statistics Virtual Journal Club, Statistics Special Interest Area Community, DIA, 2009.
16. **Evans SR**. Panelist. Interim Efficacy and Futility Analysis. FDA-Industry Workshop, 2009.
17. **Evans SR**. Statistical Careers in Biostatistics. Career Day, BCASA, Boston, MA, 2009.
18. **Evans SR**. Adaptive Designs. ACTG Group Meeting, 2010.
19. **Evans SR**. Challenges in Developing Tailored Therapies by Subgroup Identification. FDA/DIA Statistics Forum, 2010.
20. **Evans SR**. Personalized Medicine in Benefit:Risk Assessment. FDA-Industry Statistics Workshop, 2010.
21. **Evans SR**. Quantitative Benefit:Risk Evaluation with a Focus on Personalized Medicine. FDA Workshop: Using Quantitative Decision Analysis in the Regulation of Medical Devices, 2010.
22. **Evans SR**. The Statistical and Data Management Center. OHARA External Scientific Expert Group Meeting, NIH/NIDCR, 2011.
23. **Evans SR**. Benefit:risk Evaluation in Clinical Trials. CDER/FDA, 2011.
24. **Evans SR**. Panelist. Evolving Role of Data Monitoring Committees. FDA-Industry Statistics Workshop, 2011.
25. **Evans SR**. Design and Monitoring of Benefits and Risks in HIV Clinical Trials Using Prediction. ICSA, 2011.
26. **Evans SR**. Stopping Trials for Efficacy or Futility. ACTG Meeting, Washington DC, 2011.
27. **Evans SR**. On Design Issues in Clinical Trials. ACTG Meeting, Washington DC, 2011.
28. **Evans SR**. Peripheral Neuropathy in HIV. ACTG Meeting, Washington DC, 2011.
29. **Evans SR**. The Statistical and Data Management Center. ACTG Meeting, Washington DC, 2011.
30. Robertson K, Jiang J, Kumwenda J, Supparatpinyo K, **Evans SR**, Price R. A Multinational Study of Neurological Performance in Antiretroviral Therapy-Naïve HIV-1-Infected Persons in Diverse Resource-Constrained Settings. ACTG Meeting, Washington DC, 2011.
31. **Evans SR**. Benefit:risk Evaluation in Clinical Trials. The Center for Health Quality, Outcomes and Economic Research, United States Department of Veterans Affairs, 2012.
32. **Evans SR**. Benefit:risk Evaluation in Clinical Trials. NIAID/NIH. 2012.
33. **Evans SR**. What's the Question? ACTG Meeting, 2012.
34. **Evans SR**. Panelist. A Longitudinal Model and Graphic for Benefit-risk Analysis. Statistics Virtual Journal Club, Statistics Special Interest Area Community, DIA, 2012.
35. **Evans SR**. Panelist. New Approaches in the Evolution of the Independent Data Monitoring Committee (IDMC) in Clinical Trials. ICSA, 2012.
36. **Evans SR**. Discussant. Structured Benefit-Risk in the Current Regulatory Environment and the Implications for Clinical Statisticians. DIA. Boston MA. 2013
37. **Evans SR**. Statistical Considerations in the clinical trials evaluating Antibacterial Treatments. DIA. Boston MA. 2013.
38. **Evans SR**. Future Directions. SCT-FDA Benefit:Risk Workshop. Bethesda, MD. 2013.
39. **Evans SR**. Benefit-Risk Assessment in Clinical Development and Regulatory Review. DIA/FDA Statistics Forum. Bethesda, MD. 2013

40. **Evans SR.** Consider the “Order of Operations” in Benefit:Risk Evaluation. ICSA. Washington DC. 2013
41. **Evans SR.** Panelist. Help, I’m Supposed to Teach! How to Teach Biostatistics to Non-statisticians in Biomedical Environments. JSM. Montreal CA. 2013.
42. **Evans SR.** Response Adjusted for Duration of Antibiotic Risk (RADAR). Clinical Trial Transformation Initiative (CTTI) Statistical Issues Think Tank. 2014.
43. **Evans SR.** Response Adjusted for Duration of Antibiotic Risk (RADAR). FDA Statistical Association Benefit:Risk Symposium. 2014.
44. **Evans SR.** Discussant. FDA/NIH: The Development of New Antibacterial Products: Charting a Course for the Future. Bethesda, MD. 2014.
45. **Evans SR.** Using endpoint data to analyze patients rather than patient data to analyze the endpoints. JSM. Boston MA. 2014.
46. **Evans SR.** ASA: 175th Anniversary Celebration: The Future of Statistics in the Health Sciences, 2014.
47. **Evans SR.** Strength in numbers: Innovative Statistical Approaches that Clinicians Should Care About. ID WEEK. San Diego, CA. 2015.
48. **Evans SR.** Battling Superbugs with Statistical Thinking: Using Endpoints to Analyze Patients Rather than Patients to Analyze Endpoints. Mosteller Statistician of the Year Banquet. Boston Chapter of the ASA. Boston, MA. 2015.
49. **Evans SR.** Battling Superbugs with Statistical Thinking. Re-Entering Antibacterial Drug Development Summit, Boston, MA. 2015.
50. **Evans SR.** The Design of the Master Protocol for Multiple Investigational Diagnostics (MASTERMIND). SCT. Washington, DC. 2015.
51. **Evans SR.** Benefit:Risk Evaluation in Medicine: Discussant. JSM, Chicago, IL. 2016.
52. **Evans SR.** Advances in Design of Infectious Disease RCTs. Meet the Experts. ASM Microbe, Boston, MA, 2016.
53. **Evans SR,** Huskins C. DOOR and RADAR. Webinar. Centers for Disease Control and Prevention (CDC). 2016.
54. **Evans SR.** The Statistical and Data Management Center of the Antibacterial Resistance Leadership Group. NIAID. 2017.
55. **Evans SR.** Novel statistical designs in studies of antibiotic resistance. The NIAID Summer Retreat. 2017.
56. **Evans SR.** Challenges of the Clinical Use and Interpretation of Genotypic vs. Phenotypic Drug Resistance Testing. Food and Drug Administration. 2017.
57. **Evans SR.** Using outcomes to analyze patients rather than patients to analyze outcomes. World Antimicrobial Congress. Washington DC. 2017.
58. **Evans SR.** Benefit-Risk Evaluation for Diagnostics: A Framework (BED-FRAME). ENAR. Washington, DC. 2017.
59. **Evans SR.** Improving the efficiency of medical device clinical trials by combining simulations and experiments (Discussant). JSM, Baltimore, MD. 2017.
60. **Evans SR.** DMCs and Benefit:Risk. JSM, Baltimore, MD. 2017.
61. **Evans SR.** Meet the Professor. ARLG: New Methodologies. IDWEEK. San Diego, CA USA. 2017.
62. **Evans SR,** Liu Y. Healthy Disruption for Diagnostic Studies through Pragmatic Benefit-Risk Evaluation: Average Weighted Accuracy (AWA) Webinar sponsored by the Medical Devices and Diagnostics (MDD) Section of the ASA. 2017.
63. **Evans SR.** Keynote Address. Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. 2017.
64. **Evans SR.** Panelist. Incorporating Real World Evidence in Clinical Trials. Clinical Trials Transformation Initiative. Washington, DC. 2018.

65. **Evans SR.** Panelist. Decision Analysis, Risk Stratification of Diagnostic Test Performance. ASA / AdvaMed Medical Device Statistical Issues Conference. Washington, DC. 2018.
66. **Evans SR.** Panelist. Utility of Quantitative Benefit-risk Assessment for Regulatory Decision-making. ASA Biopharmaceutical Regulatory Industry Statistics Workshop. Washington, DC. 2018.
67. **Evans SR.** Healthy Disruption for Clinical Trials. JSM. 2018.
68. Liu Y, **Evans SR.** Healthy Disruption for Diagnostic Studies through Pragmatic Benefit:risk Evaluation. JSM. 2018.
69. **Evans SR.** Pragmatic Benefit:risk Assessment in Clinical Trials. Webinar for the Biopharmaceutical Section of the ASA. 2018.
70. **Evans SR.** Pragmatic Benefit:risk Assessment in Clinical Trials: A New Paradigm Using Pairwise Comparison of Patients. Society for Clinical Trials. 2018.
71. **Evans SR,** Knutsson M, Johnston SC, Amarenco P, Albers GW, Denison H, Easton JD, Jonasson J, Ladenvall P, Minematsu K, Molina CA, Wang Y, Wong KSL. Benefit:risk Assessment Using Novel Methodologies: Ticagrelor vs. Aspirin in Acute Stroke or Transient Ischemic Attack in the SOCRATES Trial. European Stroke Organization Conference. Gothenburg, Sweden. 2018.
72. **Evans SR.** Meet the Professor. ARLG: Making the impossible, possible: Pragmatic clinical trials. IDWEEK. San Francisco, CA USA. 2018.
73. **Evans SR.** Radical Pragmatism. Invited Chair's Seminar. University of Maryland. Baltimore, MD. 2019.
74. **Evans SR.** Desirability of Outcome Ranking (DOOR). 2nd Annual TMC Antimicrobial Resistance Research and Stewardship Conference. Houston, TX 2019.
75. **Evans SR.** Desirability of Outcome Ranking (DOOR). President's Lecture Series at LA BioMed at Harbor-UCLA 2019.
76. **Evans SR.** ENAR, The Desirability of Outcome Ranking (DOOR). Philadelphia, PA USA 2019.
77. **Evans SR.** Radical Thinking: Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes. Inaugural Chief Medical Officer Seminar, COVANCE. Raleigh, NC. 2019.
78. **Evans SR.** Radical Pragmatism: DOOR and SMART COMPASS. FDA. Washington DC. 2019.
79. **Evans SR.** Radical Thinking: Scientific Rigor and Pragmatism. FDA Statistical Association. Washington DC. 2019.
80. **Evans SR.** Keynote Address. Workshop in Pragmatic Trials. Denver, CO. 2019.
81. Pan Q, Jiang, Y, **Evans SR.** A Statistical Review: Why Average Weighted Accuracy, not Accuracy or AUC? ENAR, 2020.
82. **Evans SR.** The Desirability of Outcome Ranking. Cardiovascular Research Technologies (CRT) Conference. 2020.
83. **Evans SR.** Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes. JSM. 2020.
84. **Evans SR.** Pragmatic Clinical Trials. Master of Medical Sciences in Clinical Investigation, Harvard Medical School. 2020.
85. **Evans SR.** Benefit:risk Evaluation in Clinical Trials. Master of Medical Sciences in Clinical Investigation, Harvard Medical School. 2020.
86. **Evans SR.** Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes. Clinical Trials. Maternal Fetal Medicine Units. 2020.
87. **Evans SR.** Noninferiority Clinical Trials. Maternal Fetal Medicine Units. 2020.
88. **Evans SR.** DOOR STEPP. National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS). Workshop on Subgroup Analyses. 2020.

89. **Evans SR.** DOOR STEPP. Multiregional Clinical Trials / FDA Workshop on Subgroup Analyses. 2020.
90. **Evans SR.** Statistical Issues in Oncology Clinical Trials. Center for Discovery and Innovation. 2020.
91. **Evans SR.** Communicating Statistics with Stories. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. 2020.
92. **Evans SR.** Pragmatism: Finding and Answering the Important Question. Research Design Considerations for Pragmatic and Comparative Effectiveness Clinical Trials of Pain Treatments. Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials. 2020.
93. **Evans SR.** Our most important discovery: the question. National Heart Lung and Blood Institute. 2020.
94. **Evans SR.** Keynote Address. Our most important discovery: the question. ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop. 2020.  
<https://www.youtube.com/watch?v=u8JDMhD-x20&feature=youtu.be>
95. **Evans SR.** Our most important discovery: the question. NIAID / NIH, 2022.

### **International Presentations**

1. **Evans SR.** Statistical Issues and Design. Assessment of NeuroAIDS in Africa, Arusha, Tanzania, Africa, 2006.
2. **Evans SR.** Benefit:Risk Assessment in Clinical Trials. Keynote Address. Japanese Biometric Society, Kyoto, Japan, 2009.
3. Hamasaki T, **Evans SR.** Professional Training and Education of Statisticians in Drug Development. The 8th Biostatistics Forum, Kyushu University School of Medicine, 2009.
4. **Evans SR.** Data Monitoring of Clinical Trials Using Prediction. Japanese National Institute of Public Health, Tokyo, Japan, 2009.
5. **Evans SR.** Noninferiority Clinical Trials. Interfarma and ANVISA's Multidisciplinary Symposium on Noninferiority Trials in Brazil. Keynote Address. Brasilia, Brazil, 2010.
6. **Evans SR.** Panelist. International Collaborations and Networking of the Biometricians to Develop Statistical Methodologies and to Solve Global Statistical Issues. International Biometrics Conference, Kobe, Japan, 2012.
7. **Evans SR.** Using endpoint data to analyze patients rather than patient data to analyze the endpoints. PMDA, Tokyo, Japan. 2015.
8. **Evans SR.** Optimizing Clinical Trials Using Novel Designs. SCT. Liverpool, England. 2017.
9. Miyahara S, Montepiedra G, Kim S, **Evans SR**, Gupta A, Swindells S, Chaisson RE, Ramchandani R. Risk-benefit analysis using novel methods in the A5279 latent-TB clinical trial. 49<sup>th</sup> Union World Conference on Lung Health. The Netherlands, 2018.
10. **Evans SR.** Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes. Webinar. International Society for Clinical Pharmacoeconomics. 2018.
11. **Evans SR.** Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes. Webinar. Pragmatic Benefit:risk Evaluation: Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes. Biopharmaceutical Section of the ASA, 2018.
12. **Evans SR.** Ideas for AMR Clinical Trials and Diagnostic Studies. Toronto AMR Research Group, 2018.
13. **Evans SR.** Pragmatic Benefit:Risk Evaluation: Healthy Disruption for Clinical Trials and Diagnostic Studies. Deming Conference on Applied Statistics. Keynote Address. Atlantic City, New Jersey. 2018.

14. **Evans SR.** Utilization of Real World Evidence using Patient Registry Data to Support Regulatory Decision-Making. International Symposium on Biopharmaceutical Statistics Kyoto, Japan. 2019.
15. **Evans SR.** Sequential Multiple Assignment Randomized Trials for COMparing Personalized Antibiotic StrategieS (SMART-COMPASS). International Symposium on Biopharmaceutical Statistics Kyoto, Japan. 2019.
16. **Evans SR.** Keynote Address. The Catalyst to Better Answers: More Thoughtful Questions. International Chinese Statistical Association, Applied Statistics Symposium, 2021.
17. **Evans SR.** Keynote Address. The Necessary and Unrecognized Condition for “Real World Evidence”: A Pragmatic, Patient-Centric, Benefit:risk Focus. FDA / AdvaMed Medical Device Statistical Issues Conference, 2022.
18. **Evans SR.** Desirability of Outcome Ranking (DOOR). CVCT, Washington DC, 2022.
19. **Evans SR.** Legal and Statistical Issues. CVCT, Washington DC, 2022.
20. **Evans SR.** Waking up to P. MOSAIC, French Embassy, Washington DC, 2022.
21. **Evans SR.** Desirability of Outcome Ranking (DOOR). MOSAIC, French Embassy, Washington DC, 2022.

## **Other Presentations**

### ***Chair at Professional Meetings***

1. JSM: Ecological Statistics, 2002.
2. IMS Meeting: Statistics and Sports, 2003.
3. JSM: Statistics in Sports, Comparing Performance: Ranking and Rating, 2003.
4. JSM: Distance Learning - Teaching Statistics in the Health Sciences, 2005.
5. JSM: Distance Education in Biostatistics (Roundtable Luncheon), 2005.
6. SCT: Benefit-Risk Evaluation in Clinical Trials (Plenary), 2006.
7. BCASA: Statisticians and FDA Advisory Committees, 2007.
8. JSM: Luncheon, Section on Statistics in Sports, 2008.
9. Graybill Conference: The Future of the Education of Clinical Trial Statisticians, 2008.
10. Harvard- Schering-Plough Workshop: Benefits and Risks, 2008.
11. ENAR: Statisticians and FDA Advisory Committees, 2008.
12. ENAR: Education of Clinical Trial Statisticians: Changing with the Times, 2008.
13. JSM: Luncheon, Section on Statistics in Sports, 2009.
14. HSPH-Merck Workshop: Efficacy and Safety of Vaccines, 2010.
15. FDA-Industry Statistics Workshop (Session Organizer: Benefit:Risk Evaluation), 2010.
16. ICSA: Biosimilars, 2012.
17. ICSA: Issues in Infectious Disease Clinical Trials, 2012.
18. ICSA: Innovations in the Statistics Classroom, 2012.
19. SCT: DSMBs, 2013.
20. ASA: 175<sup>th</sup> Anniversary Celebration: Statistics in Sports, 2014.
21. SCT: Superbugs, 2015.
22. JSM: Superbugs, 2015.
23. SCT: Trial of the Year, 2016.
24. SCT: Pragmatic Trials, 2016.
25. BCASA: The Future of Clinical Trials, 2016.
26. World Antimicrobial Congress: Noninferiority Trials. 2016.
27. ASA Webinar on Careers in Sports Analytics. 2016.
28. JSM: Complex Clinical Trials. 2017.
29. SCT: Trial of the Year, 2017.
30. SCT: Trial of the Year, 2018.
31. CTTI: Incorporating Real World Evidence in Clinical Trials, 2018.
32. ASA Webinar on Careers in Sports Analytics. 2018.



### ***Corporations***

1. **Evans SR.** Equivalence Trials: All Trials are Not Created Equal. Pharmaceutical Product Development, Wilmington, NC, 2001.
2. **Evans SR.** Wei LJ, More Informative Monitoring of Clinical Trials Using Prediction. Schering-Plough, NJ, 2008.
3. **Evans SR.** Wei LJ, Interim Monitoring of Clinical Trials Using Prediction. Merck, 2008.
4. **Evans SR.** Special Topics in Clinical Trials. Sunovion, MA, 2010.
5. **Evans SR.** Special Topics in Clinical Trials. Alcon, TX, 2010.
6. **Evans SR.** Special Topics in Clinical Trials. Boehringer-Ingelheim, CT, 2011.
7. **Evans SR.** Benefit:risk Evaluation. Alcon, TX, 2012.
8. **Evans SR.** Benefit:risk Evaluation in Clinical Trials. Boehringer-Ingelheim, CT, 2013.
9. **Evans SR.** Benefit:risk Evaluation in Clinical Trials. Merck, 2013.
10. **Evans SR.** Using Endpoints to Analyze Patients Rather than Patients to Analyze Endpoints. Webinar. GSK. 2016.
11. **Evans SR.** Using Endpoints to Analyze Patients Rather than Patients to Analyze Endpoints. Webinar. Vir. 2017.
12. **Evans SR.** Predicted Intervals. Webinar. Vir. 2017.
13. **Evans SR.** Using Outcomes to Analyze Patients Rather than Patients to Analyze Outcomes: Pragmatic Benefit:risk Evaluation. Covance. 2019.
14. **Evans SR.** The Desirability of Outcome Ranking (DOOR). Johnson&Johnson. 2021.
15. **Evans SR.** The Desirability of Outcome Ranking (DOOR). BARDA. 2021.

### ***High Schools***

1. **Evans SR, Evans RC.** Mathematics and Statistics Activities. Navajo GED Program, Navajo Nation, AZ, 2004.
2. **Evans SR.** Biostatistics and Clinical Trials. Silver Lake Regional High School, Kingstown, MA, 2005.
3. **Evans SR.** Statistics, Biostatistics, and Clinical Trials. Silver Lake Regional High School, Kingstown, MA, 2006.
4. **Evans SR.** Statistics, Biostatistics, and Clinical Trials. Milton High School, Milton, MA, 2006.
5. **Evans SR.** The Interesting Uses of Biostatistics. The British School of Boston, 2007.
6. **Evans SR.** Biostatistics. O'Bryant School of Math and Science, 2010.
7. **Evans SR.** Superbugs and Clinical Trials. Acton-Boxborough High School, 2015.

### ***Historical Societies***

1. **Evans SR.** The Biostatistics Center of George Washington University. Montgomery County Historical Society, MD, 2023.

## University Service

### **George Washington University**

2022-2023 Search Committee for Director of the Sumner M. Redstone Global Center for Prevention and Wellness  
2021 Big Ideas Committee (Antibiotic Resistance), SPH  
2019-present APT Committee, DBB  
2019-present Curriculum Committee, DBB  
2018-2019 APT Committee, Department of Epidemiology and Biostatistics (DEB)  
2018-2019 Chair, Biostatistics and Bioinformatics Working Group, DEB  
2018 Biostatistics Department Chair Search Committee  
2018-present Website Committee, BSC

### **Harvard University**

2006-2009 Human Subjects Committee, Institutional Review Board (IRB), HSPH  
2006 Frederick Mosteller Memorial Committee, Harvard University

## Professional Society Membership and Leadership

### **Society for Clinical Trials**

2020-present DMC Planning Committee  
2020-2022 Inter-Society and International Outreach Committee  
2018-2020 Planning Committee  
2015-2020 Chair (2016-2019), Trial of the Year Committee  
2014-2018 Board of Directors  
2014-2015 Chair, Development Committee

### **American Statistical Association (ASA)**

2021-2022 Task Force on Increasing Diversity in Editorship  
2018-2020 Board of Directors  
2014-2016 Mentorship Program Mentor

### ***Section on Teaching Statistics in the Health Sciences (TSHS)***

2014 Fellows Committee  
2007, 2009 Distinguished Achievement Award Committee (Chair, 2009)  
2007-2009 Young Investigator Award Committee (Chair, 2009)  
2008 Chair, TSHS Section  
2008 Chair, Executive Committee  
2007-2008 Chair, Nominations Committee

### ***Section on Medical Devices and Diagnostics (MDD)***

2021 Chair  
2016 Program Chair

### ***Section on Statistics in Sports***

2008 Chair, Nominations Committee  
2007 Chair, Executive Committee  
2007 Chair, SIS Section  
2007 Judge, JSM Poster Competition

### ***This is Statistics***

2019 Judge, Statsketball Contest

### ***Boston Chapter***

2011, 2014 Chair, Chapter Service Award Committee

2003-2006 President  
 2007-2010 Past President  
 2001-2002 Program Chair  
 2000-2018 Planning Committee

**Committees**

2020-2022 Task Force on P-values and Statistical Significance  
 2020 Task Force on COVID-19  
 2018-2020 Founders Award Committee  
 2018-2020 Strategic Planning Review Committee  
 2018-present Caucus for Academic Representatives  
 2014-2020 Committee on Publications  
 2013-2015 Archives and Historical Materials Committee  
 2006-2011 Chair (2009-2011), Development Committee  
 2009-2010 Public Awareness Working Group  
 2009 Representative, Congressional Visit  
 2002-2004 Committee on Statisticians in Defense and National Security

**Mu Sigma Rho, the National Honorary Society for Statistics**

2009 Constitution Review Committee  
 2007-2013 Board of Directors; Secretary-Treasurer (2007-2010)  
 2004-2010 Founding Sub-Committee Member, Affiliate Chapter (BCASA)

**Conference Program Committees**

2021 Multiregional Clinical Trials (MRCT) / FDA Workshop on Subgroup Analyses  
 2020-2022 Advisor, Biopharmaceutical Section Regulatory Industry Statistics Workshop  
 2019 International Society for Biopharmaceutical Statistics (Kyoto, Japan)  
 2017 ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop  
 2016 Joint Statistical Meetings  
 2016 Antibiotic Workshop: Society for Healthcare Epidemiology of America  
 2015 Program Chair / Executive Committee, ICSA  
 2014 Program Chair / New England Statistics Symposium (NESS)  
 2014 175<sup>th</sup> Celebration of ASA Committee  
 2012 ICSA  
 2009 FDA-Industry Statistics Workshop  
 2008 ENAR  
 2008 Graybill Conference (Biopharmaceutical Statistics)  
 2008, 2010 Harvard-Schering-Plough Workshop  
 2007-present Co-Chair, New England Symposium on Statistics in Sports (NESSIS)  
 2006 Society for Clinical Trials  
 2004 International Conference on the Analysis of Genomic Data

**Home Owners Association (HOA)**

2019-present Board Member, Marwood HOA, Potomac, MD

**Professional Memberships**

American Statistical Association (ASA), Society for Clinical Trials (SCT), Infectious Disease Society of America (IDSA), International Biometric Society Eastern North American Region (ENAR), Drug Information Association (DIA), International Society for Clinical Biostatistics (ISCB), American Society for Microbiology, American Association for the Advancement of Science (AAAS), International Statistical Institute (ISI)

## **Editorial Peer Review Activities**

### **Editor-in-Chief**

2016-present *Statistical Communications in Infectious Diseases (SCID)*  
2014-2019 *CHANCE*

### **Special Section Editor**

2021-2023 Statistical Mini-Series: Independent Oversight of Clinical Trials: Protecting Patients and Scientific Integrity, *New England Journal of Medicine (NEJM) Evidence*  
2018-present Innovations in Design, Education, and Analysis (IDEA), *Clinical Infectious Diseases*

### **Advisory Editor**

2020-present *CHANCE*  
2019-present *Statistics in Biopharmaceutical Research*

### **Associate Editorships**

*CHANCE; Drug Information Journal; Public Library of Science (PLOS) Clinical Trials; Malawi Journal of Applied Sciences and Innovation; Case Studies in Business, Industry, and Government Statistics; PLoS ONE*

### **Journal Reviewer**

*New England Journal of Medicine; Nature Medicine; Statistics in Medicine; Clinical Trials; The American Statistician; Journal of Biopharmaceutical Statistics; Computational Statistics and Data Analysis; Journal of Statistics Education; CHANCE; Statistical Education Research Journal; Medical and Pediatric Oncology; Pediatric Blood and Cancer; Statistics in Sports Anthology; NeuroImage; Journal of Quantitative Analysis in Sports; PLoS ONE; Case Studies in Business, Industry, and Government Statistics; Annals of Neurology; Future Virology; European Academy of Dermatology and Venereology; Antimicrobial Agents and Chemotherapy; Clinical Infectious Diseases; HIV Clinical Trials; Circulation*

### **Grant Reviews**

- NIAID/NIH: Fecal Microbiota Transplant for *C. difficile* Infection in Solid Organ Transplant Recipients
- NIAID/NIH: Clinical Trial Grant Applications
- NIAID/NIH: Clinical Trial Planning Grant Program and Clinical Trial Implementation
- NIDCD/NIH: Clinical Trials in Communication Disorders
- NIA/NIH: New Interventions for Menopausal Symptoms
- NIMH/NIH: HIV and Psychiatric Comorbidity Research Project
- NHLBI/NIH: Cord Blood Transplantation
- NHLBI/NIH: SCCOR in Transfusion Biology and Medicine
- NHLBI/NIH: HAART: Cardiovascular Toxicities, Special Emphasis Panel

### **Other Reviews**

- Professorial Review (Rui Wang), Harvard Medical School
- Tenure Review (Dr. Ying Chen), Stanford University
- Tenure Review (Dr. Huiman Barnhart), Duke University
- Promotion Review (Dr. Thomas Holland), Duke University

- Promotion Review (Dr. Denise Esserman), Yale University
- Distinction Committee, Boston University

### **External Activities / Partnerships**

#### **Visiting Professor**

2010-2016 Department of Biostatistics and the Center for Advanced Medical Engineering and Informatics, Osaka University, Japan

#### **Secondary Appointments**

2016-2018 Faculty, Sports Analytics Laboratory, Department of Statistics, Harvard University

#### **Clinical Trials Transformation Initiative (CTTI)**

2016-present Steering Committee

2016-present Team Leader, Real World Evidence project

### **Scientific Advisory Boards, Think Tanks, and Expert Panels**

2023	External Advisory Board, Department of Biostatistics and Data Science (BDS), Division of Public Health Sciences, Wake Forest University School of Medicine
2022-present	Steering Committee: Consortium on Pain Efficacy, Effectiveness, and Safety Studies (COPESS)
2022	Invited panelist: FDA Public Workshop on Antimicrobial Drugs for the Treatment of Uncomplicated UTI
2021-present	Board of Directors, Frontier Science Foundation
2021-present	Improving the FDA Approval Process for Drugs and Vaccines Committee, Pharmedout
2021	Invited guest: FDA/NIAID/CDC Gonorrhea Virtual Workshop
2020-2021	Technical Advisory Group (TAG) for the Demonstrating Non-inferiority of Lower Dose Calcium Supplementation During Pregnancy for Reducing Preeclampsia and Neonatal Outcomes
2020	Biometrics Consortium Advisors
2019-present	Co-chair, Benefit-Risk Balance for Medicinal Products, Council for International Organizations of Medical Sciences (CIOMS).
2019	Sexually Transmitted Infections Clinical Trials Group: Considerations for Optimal Trial Design for Evaluation of Antimicrobials for Urogenital Gonorrhea.
2019	Drug Coated Balloons (DCB) Safety Town Hall; Cardiovascular Research Technologies (CRT)
2018	Margolis Center for Health Policy: Understanding the Development Challenges Associated with Emerging Non-traditional Antibiotics
2018-2022	Executive Committee: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, and Networks (ACTION)
2018-2022	Biostatistical Estimation of Net Effects for Individualization of Therapy (BENEFIT)
2018	FDA Public Workshop: Development of Nontraditional Therapies for Antibiotic Infections
2017	Consortium on Clinical Endpoints and Procedures for Peripheral Neuropathy Trials (CONCEPT)
2016-2020	QSPI: Chair of DMC Benefit:risk Working Group
2016-present	Executive Committee: THALES Trial (AstraZeneca)
2015-present	Executive Committee: SOCRATES Trial (AstraZeneca)
2015	Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMPACT)
2014	Brookings Institute: Oral Antibacterial Drug Development
2014	CTTI: Statistical Issues Think Tank
2013-2019	Quantitative Sciences in the Pharmaceutical Industry (QSPI): Benefit:Risk Working Group
2013	Preclinical Pain Research Consortium for Investigating Safety and Efficacy (PPRECISE)
2012-2013	Muscle Study Group
2011-2013	Johns Hopkins University: Novel Therapeutics in HIV Cognitive Disorders
2011	Initiative on Methods, Measurement, and Pain Assessment in Clinical Trials (IMPACT)
2011	HIV/AIDS Network Coordination (HANC): Behavioral Sciences Working Group
2007-2012	UCSD: HIV Neurobehavioral Research Center (HNRC)

### **Data Safety and Monitoring Boards (DSMBs)**

*NIH*

- Chair, Adolescent Trials Network (ATN), NICHD
- Chair, Microbial restoration in Clostridium difficile Associated Disease (CDAD), NIAID
- SARS-CoV-2 Vaccine, NIAID/NIH
- Directed Antimicrobial Therapy for CA-Pneumonia, NIAID
- Malaria Prevention in Pregnancy, NIAID
- Duchenne Muscular Dystrophy Trial, NINDS
- Antibiotics for MRSA, NIAID

### ***Industry***

- Chair, Interface Committee, IMpassion030 Clinical Trial, Breast International Group
- Chair, Gene Therapy for Sensorineural Hearing Loss, Akouos
- Chair, ABP 710 for Rheumatoid Arthritis, Amgen
- Chair, GS-9876 for Cutaneous Lupus Erythematosus, Gilead
- Chair, Varenicline tartrate for smoking cessation, Pfizer
- COVID-19, COMET-PACE, sotrovimab for COVID-19 in pediatric participants, GSK
- COVID-19 vaccine, Clover
- COVID-19 pulmonary injury, Abbvie
- COVID-19, SAB Biotherapeutics
- COVID-19, CYNK
- COVID-19, LNG
- COVID-19 study, Vir
- Influenza study Vir-2482, Vir
- DAPA MI Registry Trial, AstraZeneca
- Donanemab for Alzheimer's Disease, Eli Lilly
- TAPPAS Trial for Advanced Angiosarcoma, Tracoon
- Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia, Takeda
- Pegcetacoplan for amyotrophic lateral sclerosis (ALS), Apellis
- Pegcetacoplan in C3 Glomerulopathy or Immune-Complex Membranoproliferative Glomerulonephritis (Apellis)
- Pan-RAF Inhibitor for Pediatric Recurrent or Progressive Low Grade Glioma, DayOneBio
- Deutetrabenazine for Tourette Syndrome in Children, Nuvelution
- Head and Neck Cancer, Rakuten
- ProstAtak for Prostate Cancer, Advantagene
- Plazomicin for CRE, Achaogen
- Biosimilar for Breast Cancer, Pfizer
- Clofazimine for MDR TB
- Major Depressive Disorder, Roche/Genentech
- Muscle loss, Novartis
- Biologic in Renal Transplant, Novartis
- Bladder Pain, Taxis Biomedical
- LABA Trial for Asthma, Novartis
- QVM-149 for Asthma, Novartis
- QMF149G and QVM149C for pediatric asthma (4 trials)
- CRZ533 in myasthenia gravis, Novartis
- Alisertib for Relapsed/Refractory Peripheral T-Cell Lymphoma, Millennium
- Chantel for smoking cessation, Pfizer
- Orteronel for Prostate Cancer, Millennium
- Voriconazole for Invasive Candidiasis and Candidemia, Pfizer
- BioFoam Surgical Matrix in Liver Surgery, CryoLife/Averion

- Lersivirine for HIV, Pfizer
- PF-02545920 for Schizophrenia, Pfizer
- CP-601,927 for Major Depression, Pfizer
- Ocrelizumab for RRMS, Genentech/Roche
- Ocrelizumab for PPMS, Roche
- Cardiac Device, AAI International
- Cardiac Device, Medical and Technical Research Associates (MTRA)
- Deutetrabenazine for Moderate to Severe Tardive Dyskinesia, Teva
- Tourette's syndrome, PRA Health Sciences
- Clofazimine for MDR tuberculosis, Novartis
- CDZ173 in autoimmune disease, Novartis
- Advanced solid tumors, Five Prime
- Atypical hemolytic uremic syndrome (aHUS), Alexion
- Avelumab for ovarian cancer, Syndax
- Hemophilia, Shire
- Huntington's disease, WAVE
- Alzheimer's disease, Roche/Genentech
- Cerebral Palsy, Teva

***Academic Hospital / Other***

- Chair, MedCHEC, Boston University
- Chair, Smoking Cessation, Duke University
- Platform Trial: Therapies in Dominantly Inherited Alzheimer's Disease, Washington University
- PALbociclib CoLlaborative Adjuvant Study (PALLAS), Breast International Group
- Hydroxychloroquine Trial (HERO), Duke
- Smoking Cessation, University of Pennsylvania and PCORI
- FIRSHTD, Huntington's Study Group
- REACH2HD, Huntington's Study Group
- Endoscopic resection of large colorectal polyps, Dartmouth College
- Citalopram in First Episode Schizophrenia, Massachusetts General Hospital
- PARAFU, Johns Hopkins University
- Patent Foramen Ovale for closer of heart hole in Stroke and TIA, HCRI
- Folate with B12 for Schizophrenia, Massachusetts General Hospital
- International Studies, HIV Neurobehavioral Research Center (HNRC)
- Ziprasidone for Schizophrenia, Massachusetts General Hospital

**Teaching / Learning Portfolio**

**Courses Taught (at HPSH)**

***Primary Faculty***

- Principles of Clinical Trials (PUBH 6866 at GWU; Spring 2021)
- Principles of Clinical Trials (BST 214 at HSPH; taught for 12 semesters)
- Advanced Topics in Clinical Trials (BST 238 at HPSH: taught for 2 semesters)
- STAT E-102: Introduction to Biostatistics (STAT E-102 at Harvard University; taught for 12 semesters; traditional and distance learning)

***Secondary Faculty***



- Statistical and Quantitative Methods for Pharmaceutical Regulatory Science (BST 523 at HSPH; taught for 3 semesters)

**Guest Lecturer**

- Advanced Topics in Clinical Trials (BST 238 at HPSH). Futility and Predicted Interval Plots) 2013.
- Design and Monitoring of Adaptive Clinical Trials (BST 276 at HSPH). DSMBs and Predicted Interval Plots (PIPs). 2014.
- Design and Monitoring of Adaptive Clinical Trials (BST 276 at HSPH). DSMBs and Predicted Interval Plots (PIPs). 2016.

**Short Courses Taught at Professional Meetings and Other Venues**

2022	Data Monitoring Committees, with Stuart Pocock and David DeMets, CVCT
2021	C'mon in, the DOOR is Open, Deming Conference on Applied Statistics
2021	Data Monitoring Committees: Duke Industry Statistics Symposium
2019	Data Monitoring Committees: Society for Clinical Trials
2019	Data Monitoring Committees: FDA-DIA Statistics Forum
2019	Hot Topics in Clinical Trials: International Symposium on Biopharmaceutical Statistics
2018	Principles for New Clinical Trialists: Deming Conference on Applied Statistics
2017	ASA Biopharmaceutical Section Regulatory-Industry Statistics Workshop: Futility Analyses in Confirmatory Clinical Trials - Methods and Procedures
2017	Deming Conference on Applied Statistics: Hot Topics in Clinical Trials
2016	Osaka University Medical School: Thinking Clinical Trials
2016	Harvard Catalyst   The Harvard Clinical & Translational Science Center: A Comprehensive Tour of Modern Clinical Trials with Software
2015	FDA (CDRH): Biostatistics Lecture Series
2015	Osaka University Medical School: Thinking Clinical Trials
2015	National Cerebral and Cardiovascular Center of Japan: Clinical Trials
2013	DIA/FDA Statistics Forum: Benefit:risk Evaluation
2013	Biopharmaceutical Section of ASA (webinar): DSMBs
2013	GSK: Benefit:Risk Evaluation
2012	Osaka University Medical School: thinking Clinical Trials
2012	National Cerebral and Cardiovascular Center of Japan: Clinical Trials
2011	FDA (CDRH): Benefit:risk Evaluation in Clinical Trials
2010	FDA-Industry Workshop: Hot Topics in Clinical Trials
2010	Statistical Society of Australia / Australian Statistical Conference: Topics in Clinical Trials
2010	Deming Conference on Applied Statistics: Benefit:Risk Assessment, Subgroup Analyses, and Prediction for Interim Data Monitoring
2009	FDA-Industry Workshop: Benefit:Risk Assessment
2009	Biopharmaceutical Applied Statistics Symposium (BASS): Fundamentals for Clinical Trial Statisticians
2009	Society for Clinical Trials: Hot Topics in Clinical Trials
2009	Osaka University Medical School: Thinking Clinical Trials
2009	Harvard Medical School and the University of Sao Paulo: Clinical Trials for Scholars in Clinical Research
2009	Pharmaceutical Education Research Associates: Basic Clinical Statistics for Non-Statisticians
2009	University of Colorado: Noninferiority Trials
2008	Joint Statistical Meetings: Hot Topics in Clinical Trials

- 2008 Graybill Conference: Hot Topics in Clinical Trials
- 2008 Society for Clinical Trials: DSMBs
- 2008 Beth Israel Deaconess Medical Center, Grand Rounds Series:  
Statistical Tutorials for Clinicians
- 2008 Pfizer: Training for Clinical Trial Statisticians
- 2008-2011 American Neurological Association: Summer Course for Clinical and  
Translational Investigators in Neurology and Neuroscience
- 2007 BASS: Hot Topics in Clinical Trials
- 2007 FDA-Industry Workshop: DMCs
- 2001-2009 Pharmaceutical Education Research Institute (PERI): Basic Training Course for  
New Clinical Statisticians
- 2005 PERI: STATS 101: Introduction to Statistical Thinking in Drug Development

**Doctoral Committees**

- 2020-present Weixiao Dai, Biostatistics, GWU (primary advisor)
- 2019-present Xiaoyan Yin, Biostatistics, GWU (primary advisor)
- 2018-2022 Greg Sandoval, Biostatistics, GWU (member)
- 2017-2018 Derek MacFadden, Infectious Disease Epidemiology, HSPH (member)

**Other Mentoring**

- 2021-present Tori Kinamon, FDA Antibacterial Drug Resistance (DOOR) Fellowship
- 2019-2021 Jessica Howard-Anderson, Antibacterial Resistance Leadership Group (ARLG)
- 2017-2018 Mentor in DMID/NIAID/NIH DSMB Mentorship Pilot Program
- 2014 Host for Fogarty Fellow (Onoja Akpa, Nigeria)

**Public Health Practice Portfolio**

**Participation on Advisory Panels**

- 2001-2019 Special Government Employee (SGE), Food and Drug Administration (FDA)  
Division of Anti- Infective Drug Products, Center for Drug Evaluation and  
Research (CDER) 2001-2005; Medical Devices Advisory Committee, Center for  
Devices and Radiological Health (CDRH) (2005-2019)

**Testimony**

- 2004-2006 Expert Witness, Commonwealth of Massachusetts